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Efavirenz is an effective antiretroviral agent widely used as part of first-line regimen in HIV1-infected 
children and adults. Neuropsychiatric adverse effects are reported in up to 50% of users. These include 
dizziness, insomnia, abnormal dreams, headache and impaired concentration. The plasma level of 
efavirenz may be key in the development of these adverse effects. Even among individuals taking 
recommended doses for weight, the plasma levels vary widely. Genetic polymorphisms leading to 
different allelic variants of the CYP2B6 enzyme, making some individuals slow metabolizers may play a 
role. These allelic variants are highest in people of African descent. This report examines the 
neuropsychiatric adverse effects of efavirenz, and the strength of the data that the product may result in 
neuronal damage.  
Keywords: adverse events, children, efavirenz, HIV, neuropsychiatric. 
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It is estimated that there were 2.6 million children <15 years of age worldwide living with HIV infection at 
the end of 2014, with approximately 88% living in sub-Saharan Africa [1]. Many of these children are 
orphans and live in poorly resourced settings and, thus, face huge socioeconomic challenges. With the 
improved availability of antiretroviral therapy (ART), these children now more often follow a chronic 
disease course and experience many long-term complications, some from the infection and associated 
comorbidities, and others as a result of therapy.  
The neurologic and psychiatric manifestations in HIV-infected children may result from the infection itself, 
its secondary complications such as opportunistic infections of the central nervous system, seizures, 
cerebrovascular disease, as well as the adverse effect of ART. In addition, there is often a complex 
interplay between these processes and the multiple socioeconomic challenges faced by HIV-infected 
children living in low- and middle-income countries (LMIC) [2–5]. Frontal lobe dysexecutive function in 
HIV-infected children and adolescents is thought to be associated with poor virologic suppression (low 
CD4 count, high viral load) as well as poor socio-demographic and nutritional status (low haemoglobin 
and albumin levels). In these children, neuroimaging studies and neuropsychological testing have shown 
white matter micro-structural changes with associated cognitive decline and behavioural deterioration 
[6,7].  
Efavirenz, a widely used non-nucleoside reverse transcriptase inhibitor, was approved in 1998 for the 
treatment of HIV-1 infection. It binds to a hydrophilic pocket located in the p66 subunit of the HIV reverse 
transcriptase, which directly inhibits its activity and, thereby, prevents the conversion of ssRNA into DNA 
during viral replication [8]. Thus, it prevents the formation of new viral particles, slowing down the 
damage to the host immune system and the occurrence of AIDS-defining illnesses.  
It is well absorbed after oral administration. Following a single dose of 600 mg in adults, it reaches a 
plasma Cmax of 4.1 mcg/ml in 3–5 h [9,10]. After multiple dosing, steady-state concentrations are achieved 
between 6 and 10 days [9]. It is 99% bound to plasma albumin [9,10] with an apparent distribution volume 
of 3.8 l/kg and a bioavailability of 40–45% [10]. Its bioavailability is much enhanced if taken with fatty food 
[11]. It crosses the blood–brain barrier, and adequate concentrations are reported in the cerebrospinal 
fluid (CSF) [9,10]. At steady state, its CSF:plasma ratio (also referred to as CSF penetration) is 0.61 (range: 
0.4–1.3) [11]. It is metabolized mainly by the CYP450 isoenzyme CYP2B6 and to a lesser extent by CYP3A4, 
and has an apparent plasma clearance of 9.4 l/h and a long plasma half-life of 40–55 h [9,10]. However, it 
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induces its own metabolism through the induction of the CYP3A4 and CYP2B6 isoenzymes leading to 
decreased half-life and tolerance over time [9]. The general pharmacokinetic properties of efavirenz are 
influenced by many factors including age, sex, bodyweight, ethnicity, concomitant diseases and drug–drug 
interactions [9,11]. These interindividual variations appear to be responsible for some of the clinical 
outcomes of the drug. Due to its effectiveness, ease of administration and high tolerability, it is globally 
listed among preferred HIV treatment options [12,13] and recommended by the WHO as part of first-line 
ART [13]. However, there is clinical evidence supported by experimental data that it causes damage to 
neurons with resultant neuropsychiatric effects [14,15]. These adverse events (AEs) are reported in up to 
50% of patients [16,17]. Patients report neuropsychiatric symptoms, such as dizziness, blurred vision, 
impaired concentration, sleep disturbance, headache and loss of memory. Less commonly reported 
neuropsychiatric AEs include seizures, depression, euphoria, delusions, hallucinations, paranoia, mania 
and suicidal ideation [16–19].  
Though often reported as transient and mild, some neuropsychiatric AEs of efavirenz could be severe 
enough to lead to poor adherence or discontinuation of treatment, especially since they tend to occur 
early in the course of the treatment. Typically, the clinical symptoms of efavirenz neurotoxicity start within 
days of treatment initiation, peak after about a week or two and then finally resolve within 1–3 months 
despite ongoing treatment with efavirenz [16,17]. However, there is evidence of neurocognitive 
dysfunction associated with long-term efavirenz use in adults [20]. In children, some experts have 
predicted poor neurocognitive outcomes following efavirenz neurotoxicity [16]. There are also studies 
that suggest that the neuropsychiatric complications may persist for at least 2–3 years following efavirenz 
initiation [21,22].  
The WHO does not recommend efavirenz use in children aged <3 years or weighing <10 kg [23]. However, 
in 2013, the US FDA approved its use to include children younger than 3 years but older than 3 months 
old. This prompted the Southern African HIV Clinicians Society (SAHIVCS) to release a statement in which 
they advised against the use of the drug in younger children within the subregion, citing the 
pharmacogenetic variances of children of African descent, as well as logistic constraints for therapeutic 
drug monitoring in resource-limited settings [24]. In this statement, the SAHIVCS noted that the CYP2B6 
G>T mutation is more common in the black African population putting these children at increased risk of 
toxicity especially with the higher doses that were recommended by the FDA. Moreover, genetic testing 
for the CYP2B6 G>T polymorphism would not be available outside of research studies, and similarly the 
routine therapeutic drug monitoring to assess plasma levels of the drug and adjust doses accordingly [24].  
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This caution is not only useful in South Africa, but also in other parts of sub-Saharan Africa where the 
CYP2B6 G>T polymorphism is widely expressed [25–29]. As in South Africa, routine drug monitoring and 
genetic testing are not available in these countries. Some authors have recommended a systematic 
approach to the challenges of pediatric efavirenz dosing in sub- Saharan Africa, to include capacity building 
for therapeutic drug monitoring, treatment, laboratory and clinical monitoring for optimization of 
efavirenz in pediatric HIV programs in these regions [30,31].  
It is still debated whether the neuropsychiatric complications noted with the use of efavirenz are severe 
enough for patients to discontinue the medication or to adhere poorly. While some authors have reported 
poor adherence or discontinuation of treatment following these complications [32–36], others have 
reported that these side effects are either mild or transient and do not lead to poor adherence or 
discontinuation of the drug [37–39].  
Though CNS adverse effects are also reported in patients taking nonefavirenz-based ART regimens, they 
are most commonly reported in those on efavirenz. In a study of 408 HIV-infected children and 
adolescents in Uganda [39], a total of 378 patients were started on ART; 177 on efavirenz-based ART 
regimens and 201 on nonefavirenz-based ART regimens. There were a total of 39 reported CNS adverse 
effects including impaired concentration, dizziness, amnesia and nightmares. Twenty-five patients out of 
the 177 (14%) on efavirenz-based ART reported CNS-related AEs as compared with 14 patients from the 
201 (7%) on nonefavirenz-based ART regimens [39]. Though some antiretroviral drugs including both 
nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs), as well as protease 
inhibitors (PIs), have been associated with CNS adverse effects [40,41], it must be noted that the incidence 
of neuronal toxicity in efavirenz is much higher [16,17].  
This report will examine the neuropsychiatric AEs reported due to efavirenz. It will assess the strength of 
the data to support the suggestion that the product may result in neuronal damage. It will also examine 
the pharmacogenetic factors that may predispose children from some ethnic groups to neuronal toxicity. 
 
Commonly reported neuropsychiatric AEs of efavirenz  
While there are many clinical trials that report neuropsychiatric complications of efavirenz in adults [42–
47], only one is published in children [27]. There are, however, a few case reports [34,48] and 
observational studies [33,36,37,39,49,50] that report neuropsychiatric complications of efavirenz in 
6 
 
children. The published case reports, observational studies and one randomized controlled trial in children 
are summarized in Table 1. 
Sleep disturbances  
Sleep disorders including insomnia, vivid dreams and nightmares are commonly associated with the 
initiation of efavirenz therapy in both children and adults [16,37–39]. In the first switch study in children 
aged 2–13 years old in 2003 in which protease inhibitors were substituted with efavirenz [37], the authors 
reported that two out of the 17 children studied had unusual vivid dreams after they were started on 
efavirenz while one child also reported insomnia. Mid-dose plasma efavirenz concentrations were not 
done [37]. In another prospective study to assess the safety and tolerability of ARTs among HIV-infected 
children and adolescents aged 3–18 years old in Uganda, nightmares were reported by eight out of 177 
children who received efavirenz [39]. In adults taking efavirenz, a prospective study that assessed the 
quality of sleep through patient self-report showed an increase in vivid and unpleasant dreams, an 
increased recollection of dreams and an overall decrease in sleep quality [38].  
The unusual vivid dreams following efavirenz initiation tend to decrease in frequency and intensity after 
the first 3 months [37], and often do not lead to treatment interruption, but are still potential reasons for 
some patients to discontinue the drug as they impact negatively on the quality of sleep. Out of five 
children who reported nightmares in an observational study in France, only one discontinued treatment 
[36]. In the Ugandan study, none of the eight children who reported nightmares discontinued treatment 
[39]. In a retrospective study of ten children aged 3–8 years, Funk et al. [50] reported efavirenz dose 
reduction in one child who experienced abnormal dreams and depression and whose plasma level was 
found to be 24.2 mg/l, over six times the upper limit of normal. 
Impaired concentration  
Impaired concentration, drowsiness or mental slowing are the most frequent CNS adverse effects of 
efavirenz, reported in up to 50% of people taking the drug, in both children and adults [18,33] Mental 
slowing, drowsiness and later coma were reported in a black South African male adult who later 
succumbed to aspiration pneumonia [51]. In children, this effect is reported in two prospective studies 
from Uganda [39] and The Netherlands [33]. The mid-dose plasma efavirenz concentration was not done 
in the Ugandan study [39], but in the Dutch study it was reported to be increased in a total of 45 (14.7%) 
of samples tested, mainly from those who reported adverse effects [33].  
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The impaired concentration following efavirenz intake is thought to be due to a direct toxic effect of the 
medication on the brain and also the indirect effect of poor night-time sleep on initiation of the 
medication [33,38]. Thus, patients suffer poor concentration in the morning after a night-time dose. This 
coupled with visual blurring or dizziness makes it difficult for patients to go about their normal activities 
of daily living. In children, it is even more problematic when they need to go to school in the morning. In 
the Dutch study, six out of the eight children who reported AEs (five concentration problems, one sleep 
disorder, one psychotic reaction and one seizure) discontinued the medication [33]. 
Neurocognitive dysfunction  
Poor neurocognitive outcomes have been reported in adults after long-term use of efavirenz. In a 
retrospective cohort study of 445 adults in which the long-term impact of efavirenz was compared with a 
comparator (lopinavir with ritonavir) [20], all patients completed standardized comprehensive testing that 
assessed various cognitive abilities namely speed of information processing, learning, recall, executive 
function, verbal fluency, working memory, attention and motor function. The mean duration of use was 
1.5 years with good adherence in both groups. Overall, the efavirenz users had worse performance in 
most neurocognitive abilities than the lopinavir with ritonavir users, particularly verbal fluency, working 
memory and speed of information processing [20].  
In children, the impact of efavirenz on neurocognitive outcome has not been reported. The poor 
neurocognitive ability of some children with perinatally-acquired HIV infection is largely attributed either 
to the direct effect of the virus on the brain, a condition termed HIV-related encephalopathy, or to one of 
the many comorbidities, such as neuroinfections, cerebrovascular disease and epilepsy [2–5]. However, 
with the current evidence that long-term efavirenz use causes neurocognitive dysfunction in adults, there 
is the potential that these manifestations could also occur in children. 
Dizziness & visual disturbances  
Dizziness is well documented as an adverse effect of efavirenz, usually reported as mild and often 
experienced only in the first few months of starting treatment [36,37,39,49]. In a randomized control trial 
of 57 children aged 3–16 years, Starr et al. [32] tested the safety and antiviral efficacy of an ART 
combination consisting of efavirenz, nelfinavir and one or more NRTIs. The children were monitored for 
48 weeks after the initiation of therapy and pharmacokinetic studies were done to determine the mean 
values for 24-h area under the concentration-time curve at weeks 2 and 6. Dizziness, reported by eight 
out of the 57 children, was the only CNS AE noted. It was reported as mild and resolved once efavirenz 
was given at bedtime, and no child discontinued treatment as a result [32]. However, in an observational 
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study in 33 French children aged 10–14 years, one child reported persistent dizziness leading to 
discontinuation of the drug [36]. Ten others also reported dizziness but these were transitory and did not 
result in drug discontinuation [36].  
The feeling of dizziness and mental slowing are usually most intense in the hours leading up to the peak 
in drug level, usually about 4 h after dosing. Thus, to minimize this effect on the patient’s concentration 
and vision, it is recommended that the medication should be taken at bedtime [52]. However, night-time 
dosing also increases the incidence of sleep disorders particularly nightmares and unpleasant dreams and, 
as such, some patients prefer to take the medication in the morning to avoid these sleep disturbances 
[52].  
Blurred vision has also been reported following efavirenz ingestion [48]. In the case of a 12-year-old 
Ugandan boy who accidentally ingested 3 g of efavirenz (7.5 times the recommended therapeutic dose 
for his weight), he had impaired vision to near objects that occurred within 1 h of ingesting the drug. He 
was admitted to hospital for 4 days and responded well to supportive treatment, though plasma levels of 
efavirenz were not done. Ten days following the ingestion of the drug, his vision had normalized [48].  
Varying outcomes are reported following the visual disturbances or dizziness in children taking efavirenz; 
with either discontinuation of the drug [36] or continued adherence in spite of the dizziness and visual 
disturbances [37,39]. 
Psychiatric reactions  
Psychiatric reactions including hallucinations, depression, suicidal ideation, aggression, paranoia and 
mania are described [33,35,36,50,53,54], but their association with efavirenz use is controversial with 
divided opinions. While some authors link these reactions to efavirenz use [36], others are of the opinion 
that these AEs are more common in people with a history of psychiatric disorders [53]. A third group of 
authors argue that there are no links between these effects and efavirenz use [54].  
Out of ten children who received first-line triple therapy including efavirenz in a retrospective study, one 
child was reported to be depressed. There was no previous history of psychiatric illness in this child. 
Pharmacokinetic evaluation revealed high peak plasma efavirenz levels and the dosage of efavirenz was 
subsequently reduced with improvement in her condition [50].  
In the observational study of 33 children in France who were given efavirenz in combination with other 
ART drugs, two children had a recurrence of pre-existing psychiatric problems. Efavirenz was discontinued 
in one child. A third child with no previous history of psychiatric disorder also presented with apathy and 
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confusion following two nights of nightmares leading the parents to discontinue treatment with efavirenz 
[36].  
Hallucinations and paranoia are reported in adults leading to discontinuation of efavirenz treatment [35]. 
There is also a concern about an increased risk of suicidal ideation in adults who receive efavirenz, but 
this is also debated [17,18,54–56]. A recent meta-analysis of four large randomized clinical trials in ART-
naive adults suggested that there is a two-fold increased hazard of suicidality (suicidal ideation, attempted 
suicide or completed suicide) in efavirenz users compared with non-efavirenz users [56]. However, no 
such association has been described in children.  
In view of these psychiatric AEs described above, efavirenz is contraindicated in patients with significant 
psychiatric comorbidities [17,57], and in these patients, it is replaced by nevirapine or lopinavir/ritonavir. 
Adults with active psychiatric illness being considered for efavirenz therapy should be evaluated in terms 
of suicide risk [17]. 
Others CNS manifestations  
Seizures, headache, amnesia, neuropathies and tremors are reported following treatment initiation with 
an efavirenz-containing regimen [33–37,39,48]. Absence seizures associated with efavirenz initiation were 
reported in a case of a 5-year-old black South African girl [34]. She was diagnosed with perinatally acquired 
HIV-1 at age of 52 days and started on an ART regimen containing a PI and two NRTIs. She had a good 
immune response and viral suppression on this regimen. At age of 4.5 years, she was enrolled into a 
clinical trial and randomized to substitute efavirenz for the PI. One month postrandomization, she was 
presented with staring episodes lasting less than a minute and occurring two to three times in a day. She 
always recovered completely from these episodes without any postictal drowsiness. Her EEG showed 
generalized burst of high amplitude slow waves and generalized polyspikes, and her mid-dose plasma 
efavirenz concentration was 19.62 mg/l, almost five times greater than the upper limit of normal. 
Efavirenz was discontinued and the PI restarted, and the staring episodes abated after 1 month. She also 
had normal EEG 2 months after discontinuing efavirenz [34].  
In another case report, a 45-year-old female was reported to have multiple generalized seizures and later 
had status epilepticus following marked efavirenz toxicity [35]. Her mid-dose plasma efavirenz level was 
over fourfold greater than the upper limit of normal. On stopping the efavirenz, these symptoms resolved 
but recurred when the drug was reintroduced at a lower dosage. The efavirenz was again stopped and 
her symptoms resolved completely [35]. 
10 
 
Headache is reported as one of the CNS adverse effects of efavirenz in children [36]. Six out of the 33 
children who were treated with combination ART including efavirenz reported headaches, and two 
discontinued treatment as a result of the headache. The plasma levels of efavirenz were not determined 
in this study. Also, the authors did not give further details of the headache or whether it resolved after 
discontinuing the medication [36].  
Tremors and motor deficits were reported in the 12-year-old African boy who accidentally ingested 3 g of 
efavirenz as a single dose. Additional neuropsychiatric AEs reported in this child include visual impairment 
and screaming at night [48].  
It is important to note that some substances of abuse give similar CNS effects as those reported in 
efavirenz users. There are anecdotal reports that efavirenz may be misused by HIV patients and 
noninfected teens who crush the pill and smoke the powder for its psychoactive effects [58]. Animal 
studies have demonstrated similar mechanisms leading to the CNS effects of efavirenz and substances of 
abuse, such as lysergic acid diethylamide, cocaine and methamphetamine [58]. These findings correlate, 
in part, with the subjective experiences in humans who abuse efavirenz to generate specific 
neuropsychiatric events, such as hallucinations, vivid dreams and night terrors [58]. 
 
Pharmacogenetic factors leading to efavirenz toxicity  
To be effective, antiretroviral drugs must reach therapeutic levels in the CNS, which is an important viral 
reservoir. There is evidence that efavirenz readily crosses the blood–brain barrier through simple diffusion 
[11]. It is hypothesized that the incidence of CNS adverse effects correlates more with the CSF 
concentration than with the plasma concentration. This, however, has not been tested in children. Even 
in adults, only a few studies have actually assessed efavirenz levels in the CSF [59–62]. In most phar-
macokinetic studies, only plasma levels have been tested and the incidence of neuropsychiatric AEs has 
been found to correlate with the mid-dose plasma concentration measured at 12–15 h after taking the 
drug [33,34]. The exact plasma levels above which patients experience these AEs are reported differently 
from various studies [17,63,64], but mid-dose plasma concentrations between 1–4 mg/l have been 
observed to achieve maximal control/suppression of viral replication and are relatively safe in terms of 
short-term AEs [33,50].  
In general, younger children often have increased metabolism of drugs compared with older children and 
adults and, therefore, require higher doses in order to maintain therapeutic plasma drug concentrations 
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similar to adults. In the case of efavirenz, dosing is done according to weight bands, with comparatively 
higher doses offered to younger children. For example, to maintain therapeutic plasma levels, the 
recommended doses for a 3-year-old child weighing 15 kg, an adolescent weighing 35 kg and an adult 
weighing 70 kg are 250, 400 and 600 mg once daily, respectively [65]. This means the dosage per 
bodyweight per day in these individuals will be 16.7, 11.4 and 8.6 mg/kg/day, respectively.  
Although the mechanism of neuronal damage due to efavirenz remains unknown and requires more 
exploration, recent in vivo and in vitro studies have started to clarify these mechanisms. Animal studies 
have shown that efavirenz induces CNS effects through: upregulated production of proinflammatory 
cytokines; increase in serotonin levels; acting as partial agonist of the serotonin receptors; disruption of 
mitochondrial functions and neuronal handling of glucose and oxygen (bioenergetics); inhibition of 
creatine kinase activity in different regions of the brain; and inhibition of mitochondrial enzymes in the 
cerebral cortex, hippocampus and striatum [11]. In humans, recent in vitro studies have shown that 
efavirenz disrupts brain mitochondrial function and compromises cell viability by diminishing oxygen 
consumption rapidly in both neurons and glial cells [11,15,66]. As a result, there is a significant increase 
in the production of reactive oxygen species and a major decrease in mitochondrial membrane potential, 
negatively affecting cell viability. Further, it alters the cellular handling of glucose and oxygen leading to 
intracellular ATP reduction [11,15].  
Efavirenz is mainly metabolized in the liver by the CYP450 isoenzyme CYP2B6 into 8-hydroxy-efavirenz. 
This isoenzyme CYP2B6 metabolizes over 90% of the drug. Another isoenzyme CYP2A6 metabolizes about 
8% of the drug to 7-hydroxy-efavirenz and the remaining 2% is conjugated to efavirenz-glucuronide by the 
enzyme UGT2B7 [11,16]. In patients who ingest normal therapeutic doses of the drug, toxicity usually 
results from decreased metabolism due to expression of a genetic polymorphism in the CYP2B6 isoenzyme 
[67,68], drug–drug interactions [68,69] or hepatic or renal dysfunction [67]. 
Genetic polymorphism  
A single nucleotide polymorphism in the CYP2B6 isoenzyme leads to a base change at the position 516 
from G to T (CYP2B6–516G>T) and results in three different allelic variants (CYP2B6–516 G/G, CYP2B6–
516 G/T and CYP2B6–516 T/T). Individuals with the heterozygous G/T and the homozygous T/T allelic 
variants express low levels of the CYP2B6 activity, compared with those with the homozygous G/G variant. 
This leads to decreased metabolism of the drug, and thus increased plasma concentrations putting these 
individuals at higher risk of efavirenz toxicity [11,68].  
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The CYP2B6–516G>T mutation is extensively described in the indigenous African (black) population in 
South Africa. In a study of 142 South Africans in which genotyping results were available from 122 
participants (including 104 participants of indigenous African ancestry), 49% (50 blacks and ten other 
ancestries [nonblacks]) had the G/G genotype, 38% (40 blacks and ten nonblacks) were G/T heterozygotes 
and the remaining 13% (14 blacks and two nonblacks) were T/T homozygotes [68].  
There were also differences in the median efavirenz plasma concentrations among the different 
genotypes. Individuals with the G/G genotype maintained a median efavirenz concentration of 1.6 mg/l 
(IQR: 1.0–2.7) while those with the G/T and T/T genotypes maintained higher median concentrations of 
2.1 mg/l (interquartile range [IQR]: 1.6–4.7) and 5.9 mg/l (IQR: 3.6–6.8), respectively. Thus individuals with 
the T/T genotype (mostly blacks) had mid-dosing plasma concentrations higher than the recommended 
normal range of 1–4 mg/l, and also presented with higher incidence of neuropsychiatric complications, 
notably severe sleep disturbances [68].  
The CYP2B6 516G>T polymorphism is also reported in black populations from other parts in sub-Saharan 
Africa [26–28,30], and in some nonwhite populations outside Africa [67,70]. In the USA, it is reported to 
be more common in African–Americans than in Caucasian Americans [67]. 
Drug interactions between antiepileptic drugs & efavirenz  
Children infected with HIV are at increased risk of both infections of the CNS, and neurological deficits 
due to the direct effects of this neurotropic virus, with the result that seizures and epilepsy are common 
among these individuals [5]. As such, the concurrent use of ART and antiepileptic drugs (AED)s is 
inevitable, bringing with it issues of potential interactions between ART and AEDs. Of greatest concern is 
the P450 enzyme induction effect of the older-generation AEDs (phenobarbitone, phenytoin and carba-
mazepine) potentially interfering with effective plasma levels of ARTs metabolized by the P450 enzyme 
system, including efavirenz [71]. These drug interactions may either induce the metabolism of one drug 
and thereby decrease its plasma concentration or slow down its metabolism leading to toxic levels of the 
drug in the patient. Interactions that decrease AED levels could lead to loss of seizure control while those 
that reduce ART levels will result in virologic failure, resulting in immunologic decline, clinical disease 
progression and development of ART resistance [71].  
These drug–drug interactions are even more important in resource-limited settings namely in many parts 
of sub-Saharan Africa where the management of seizures is still heavily dependent on the use of the older 
generation AEDs, which are also enzyme inducing. A joint panel of the American Academy of Neurology 
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and the International League Against Epilepsy (ILAE) made recommendations for the coadministration of 
ARTs (including efavirenz) and AEDs [71]. The panel found that the efavirenz levels defined as the area 
under the concentration-time curve were not significantly affected when coadministered with valproic 
acid. Based on this evidence, they recommended that the coadministration of valproic acid and efavirenz 
may not require efavirenz dose adjustment. This recommendation was graded level C evidence (derived 
from only one study with very limited populations evaluated). They, however, did not find sufficient 
evidence to support or refute pharmacokinetic interactions between efavirenz and the other enzyme-
inducing AEDs (phenobarbitone, phenytoin and carbamazepine) and recommended that it may be 
important to avoid enzyme-inducing AEDs in people on ART regimens that include efavirenz [71]. 
The authors acknowledged that most of the evidence on which these recommendations were based, were 
from studies of limited adult populations [71], and so their application to the pediatric age group should 
be done with caution. 
HIV/TB coinfection & impact on efavirenz metabolism  
Many children with HIV infection also acquire TB infection and require concomitant treatments with anti-
tuberculous and antiretroviral therapies. This scenario is also a potential source of drug–drug interactions 
as it includes the use of enzyme-inducing medications notably rifampicin and isoniazid.  
Rifampicin, a widely used anti-tuberculous drug, induces hepatic enzymes including the CYP450 
isoenzyme CYP2B6, the main enzyme involved in the metabolism of efavirenz [72]. Findings from studies 
that explored the effect of rifampicin-based anti-tuberculosis therapy on efavirenz mid-dosing interval 
plasma concentrations showed that in patients taking efavirenz, the addition of rifampicin-based anti-
tubercular therapy decreases the mid-dosing efavirenz concentration, and this may have a negative effect 
on HIV viral suppression [68,73]. This has led to some authors suggesting an increase in the dosage of 
efavirenz in adults to 800 mg once daily when coadministered with rifampicin [73]. In children, recent 
pharmacokinetic studies found that rifampin-based anti-tuberculosis treatment was not associated with 
reduced plasma efavirenz concentrations, and did not support increasing efavirenz doses in the pediatric 
population [74,75].  
Recent adult studies have reported that rifampicin-containing anti-tuberculosis regimens may on occasion 
cause a paradoxical elevation in plasma efavirenz concentration. This increased exposure, which may 
precipitate neurotoxicity, is the result of CYP2B6 loss-of-function polymorphisms [76–78].  
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Isoniazid coadministration with efavirenz in adults may cause a mild decrease in the efavirenz mid-dosing 
plasma concentration without clinically meaningful reduction in viral suppression [79]. However, recent 
evidence suggests that isoniazid may also contribute to elevated efavirenz concentrations by inhibiting 
CYP2A6, an important pathway for metabolizing efavirenz in individuals who are CYP2B6 slow 
metabolizers. Isoniazid is usually metabolized by the enzyme NAT2. 
Loss-of-function polymorphisms in NAT2 causes increased isoniazid exposure, increasing the risk of 
CYP2A6 pathway inhibition. Furthermore, individuals with slow metabolizer phenotypes for both CYP2B6 
and NAT2 genes have been shown to have markedly elevated efavirenz concentrations when cotreated 
with rifampicin-containing anti-tuberculosis therapy [77,80].  
The WHO [81] and the CDC [82] have specific guidelines for the management of HIV and tuberculosis 
coinfections. They recommend that patients receive rifampicin during the initial and continuation phases 
of TB treatment, and efavirenz-based ART after the initial phase or as soon as the TB treatment is tolerated 
[81,82]. 
 
Conclusion & future perspective  
Efavirenz commonly causes early neuropsychiatric AEs that are usually mild and transient, resolving within 
1–3 months of starting treatment in most patients. However, some children are reported to have severe 
neuronal toxicity leading to poor adherence, discontinuation of treatment or poor neurocognitive 
outcomes. Some authors have recommended routine monitoring of therapeutic drug levels, but there is 
no strong evidence to support this. Also, there are controversies surrounding the use of efavirenz in 
children aged <3 years old or weighing <10 kg.  
There is the need for further studies to better understand the scope and mechanisms of the neuronal 
damage hypothesized to be associated with efavirenz use in HIV-infected children, as well as the 
contribution of various pharmacogenetic factors and drug interactions that affect its metabolism. In low- 
and middle-income countries where second-line AEDs may not be available, priority should be given to 




Executive Summary  
• Transient neuropsychiatric adverse effects are common in both children and adults who receive 
efavirenz.  
• Commonly reported adverse effects in children include dizziness, insomnia, nightmares, impaired 
concentration and headache.  
• Cases of seizures, ataxia and psychiatric reactions, such as depression and hallucination have also 
been reported. In some adults, the use of efavirenz has been associated with increased suicidality.  
• Long-term efavirenz use may lead to poor neurocognitive outcome in children. Worsening 
performance in verbal fluency, working memory and speed of information processing have been 
reported in adults using efavirenz.  
• The mechanism of neuronal damage due to efavirenz remains unknown but disruptions in brain 
mitochondrial function and altered cellular bioenergetics are thought to play a role.  
• Bodyweight, age, sex, genetic factors and drug–drug interactions may influence efavirenz metabolism 
and play key roles in the neuronal toxicity.  
• Dose adjustments have been suggested by some authors but the lack of routine therapeutic dose 
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Table 1: Published cases of efavirenz neurotoxicity 
Publication Type of 
study 
No. of cases & 
demographic 
details 
Dose of EFV 
ingested 
Mid-dose EFV conc. 





Kenyon et al.[51] 
2012 
South Africa 
Case report N=1 adult 






Increased (13mg/L 5 
days after stopping 
EFV) 




Drowsiness, and later coma 
EFV discontinued 
but patient died 
from aspiration 
pneumonia 







Age: 3-18 years 











treatment. 8 lost 





Case report  N=1 child 
Male 
Age 12 years 
Race: B 
Accidental 
ingestion of 3 
grams of EFV 










Case report N=1 child 
Female 


























in 14.7% of samples 
8-20h after last dose 
Impaired concentration 
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Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on 
neurocognition is unknown. Genetically determined black South Africans who are slow metabolizers of 
efavirenz may be at risk of toxicity. This study describes neuropsychiatric and neurocognitive 
manifestations of South African children with suspected efavirenz neurotoxicity.    
Methods: This retrospective study describes clinical features of 12 children with suspected efavirenz 
neurotoxicity (2008 – 2014).     
Results: Twelve children were referred (aged 3 years 4 months to 12 years, mean 7 years 8 months; 8 
indigenous African (black) and 4 mixed ancestry). Six had acute neuropsychiatric manifestations after 2-8 
weeks (mean 5 weeks) on efavirenz including drowsiness, seizures, sleep disturbances, behavioural 
changes, ataxia and slurred speech. Symptoms resolved over a few weeks in four. Two black children were 
phenotypically slow metabolizers with high plasma efavirenz concentrations above normal range resulting 
in discontinuation of efavirenz. Nine children had neurocognitive concerns potentially exacerbated by 
long-term efavirenz (6-72 months therapy; mean 31 months), and showed poor performance in all 
neurocognitive domains. 
Conclusion: Efavirenz causes transient neuropsychiatric adverse effects and may contribute to poor long-
term neurocognitive outcomes in HIV-infected children. Genetically slow metabolizers are at risk of 
neurotoxicity. Prospective studies comparing efavirenz-treated and efavirenz-naïve children are needed. 
Key words: Efavirenz, neuropsychiatric, neurocognitive, children, South Africa. 
 
What this paper adds 
• Transient neuropsychiatric manifestations are common in South African children receiving 
efavirenz. 
• Efavirenz may contribute to poor neurocognitive outcomes seen in HIV-infected children often 







By 2016 an estimated 320,000 children with HIV infection, between 0-14 years of age, were living in South 
Africa, with antiretroviral therapy (ART) coverage reaching about 55%.1 Efavirenz (EFV), a highly potent 
non-nucleoside reverse transcriptase inhibitor, is a first-line ART drug widely used by HIV-infected children 
and adults. A once-daily dose is usually given at night. Despite its efficacy and ease of administration, 
there is emerging clinical evidence, supported by experimental data, that it causes damage to neurons 
with resultant neuropsychiatric adverse effects.2  
Transient neuropsychiatric effects occur in up to 50% of people receiving efavirenz and include dizziness, 
blurred vision, impaired concentration or drowsiness, insomnia, nightmares, headache, mood changes 
and seizures.3–5 Psychiatric manifestations, more common in adults, include depression, euphoria, 
delusions, hallucinations, paranoia, mania and suicidal ideation.3–5 Symptoms often start within days of 
treatment initiation, peak after a few weeks and resolve within 1-3 months despite ongoing treatment.3,4  
Poor long-term neurocognitive outcomes such as worsening performance in verbal fluency, working 
memory and speed of information processing in adults are reported after prolonged use of efavirenz.6     
The mechanism of the neuronal damage in efavirenz toxicity remains unknown. Disruptions in brain 
mitochondrial function and altered cellular bioenergetics are suggested processes.2,7,8 There is wide inter-
individual variation in efavirenz metabolism influenced by age, sex, body weight, ethnicity, concomitant 
diseases and drug interactions.7,9 The drug is mainly metabolized in the liver by the CYP450 isoenzyme 
CYP2B6.10 In people of African descent, a single nucleotide polymorphism (SNP) in the CYP2B6 isoenzyme 
results in three different allelic variants with some individuals expressing decreased enzyme activity. 
These individuals are slow metabolizers of the drug and at risk of neurotoxicity.7,11,12 
Although this SNP is widely reported in black (indigenous African) South Africans,12 and cases of 
neuropsychiatric manifestations in this population are published,13–15 there is no study describing the 
central nervous system (CNS) complications of efavirenz in South African children. Thus, the scope and 
nature of the transient neuropsychiatric manifestations seen in children who receive efavirenz and how 
its long-term use impacts on their neurocognitive outcomes is unknown.  
This study describes the neuropsychiatric and neurocognitive manifestations in children following 
treatment with efavirenz-based ART.  
 
Method 
This is a retrospective case series of 12 children who were referred to the Neuro-HIV clinic of the Red 
Cross War Memorial Children’s Hospital (RCWMCH) in Cape Town, South Africa. RCWMCH is the largest 
children’s hospital in sub-Saharan Africa, providing multidisciplinary care at an international level within 
the constraints of a resource-limited country. The Neuro-HIV clinic is a referral clinic for children with 
neurological complications of HIV. The service reviews an average of 50 new cases a year, with most 
children diagnosed with HIV-associated neurocognitive dysfunction (HAND), HIV encephalopathy (HIVE) 
or other specific neurologic conditions such as epilepsy, complications of secondary CNS infections, 
developmental delay, learning difficulties and behavior problems.16 Children are evaluated clinically and 
investigated with neuroimaging, electroencephalogram (EEG) and other neurophysiological testing where 
indicated. Neuropsychology assessments are completed where relevant. Children with suspected 
29 
 
efavirenz neurotoxicity have additional laboratory investigations including mid-dose plasma efavirenz 
levels.    
Children were identified through the clinic database and were included if diagnosed with HIV infection, 
have received efavirenz, and had reported neuropsychiatric side-effects following efavirenz initiation. 
Children were excluded if they had CNS infection or other chronic neurological or psychiatric illness prior 
to efavirenz initiation. Data was collected on demographics, socioeconomic status, relevant medical 
histories, neuroimaging and laboratory reports. Neuropsychiatric manifestations following efavirenz 
initiation were noted. Duration on efavirenz-containing ARTs at the time of referral and the mid-dose 
plasma efavirenz concentrations which were analyzed at the University of Cape Town (UCT) pharmacology 
laboratory were recorded. 
Neuropsychology reports, where available, were included for additional neurocognitive complications. All 
neuropsychology tests were conducted by a neuropsychologist. The test battery included all 10 core 
subsets from the Wechsler Intelligent Scale for Children – Fourth UK Edition (WISC IV) to obtain a full-
scale IQ score as well as subscale scores in verbal comprehension, perceptual reasoning, working memory 
and processing speed. Aspects of executive functioning including visuospatial planning, problem solving, 
frustration tolerance and ability to understand and follow rules were assessed using the Delis-Kaplin 
Executive Function System Tower task (D-KEFS). Both the WISC IV and the D-KEFS are internationally 
recognized neuropsychological tests also used by neuropsychologists in South Africa. In children whose 
first language is not English, an interpreter was used during the testing. The developmental assessment 
reports were included for children who were assessed in the child development service using the Molteno 
Adapted Scale. School reports where available were also included.  
All caregivers gave consent for inclusion of the child’s details in the clinic database. The UCT Faculty of 
Health Sciences Human Research and Ethics Committee approved the study (HREC 479/2016) while the 
RCWMCH Research Committee granted permission for the study.   
 
Results 
Between 2008-2014, 12 children were referred with suspected efavirenz neurotoxicity. The children were 
aged between 3 years 4 months to 12 years (mean 7 years 8 months), and comprised of 5 males and 7 
females. Eight children were of indigenous African (black) ancestry and 4 of mixed ancestry.  
Table 1 summarises the study group demographics and key findings. Table 2 provides the individual case 
overviews, while table 3 summarises efavirenz usage and the neuropsychiatric and neurocognitive 
manifestations.  
Acute neuropsychiatric manifestations were reported in 6 of the 12 children; namely impaired 
concentration or drowsiness (5/12), seizures (3/12), sleep disturbances (2/12), behavioural or personality 
changes (2/12), acute ataxia (1/12) and slurred speech (1/12). All 6 children had more than one complaint: 
four had 2 manifestations, one had 3 and another had 4. These manifestations occurred within 2-8 weeks 
(mean 5 weeks) after starting efavirenz. Patient 2 had seizures and impaired concentration 6 months after 
starting medication and patient 9 had behavioural and personality changes reported but the duration on 
efavirenz was not recorded. Of the 4 children who had seizures, 2 were generalized seizures and 2 were 
focal seizures. Five children had poor concentration and school performance with concern that symptoms 
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were exacerbated by efavirenz. Direct correlation with change in performance at the time of initiation of 
treatment was not documented by caregivers, limiting direct assumption of causality. 
Eleven children had documentation on neurocognitive, developmental or academic assessments. These 
included neuropsychology assessments for 6 children, developmental assessments for 4 children and 
school reports for 7 children. These findings were captured as the long-term neurocognitive 
manifestations and included low to poor performances in processing speed (5/11), intelligent quotient 
(IQ) (5/11), attention span (4/11), working memory (4/11), verbal comprehension (3/11), perceptual 
reasoning (3/11), executive functioning (2/11), and visuospatial ability (1/11) as well as delayed fine motor 
skills (3/11) and speech/language development (3/11); all of which became evident after long-term use 
of efavirenz and ultimately led to academic underachievement in 6 children. Multiple complaints were 
common with one child having 6 manifestations, four had 5 manifestations and two had 3 manifestations.  
The total duration on efavirenz at the time of referral to neurology was known for 10 children (range 6-
72 months, mean 31 months) and unknown for 2 children but treatment was assumed to be established 
as neither reported acute manifestations.  
Mid-dose plasma efavirenz concentration was done for 10 children. Levels ranged from 0.8 to 69 mg/L 
(normal reference range 1-4 mg/L). Two children (patients 1 and 6) had high (toxic) levels of plasma 
efavirenz concentrations (69.0 and >20.0 mg/L respectively). Mid-dose plasma efavirenz concentrations 
were within normal limits for 8 children.  
Illustrative case summaries follow for patients 1 and 6 who had toxic plasma levels of efavirenz:    
Patient 1 is a male child of indigenous African (black) ancestry referred to the neurology service in 2008 
at 3 years 6 months of age with acute efavirenz neurotoxicity. After an unremarkable birth and postnatal 
course, he was diagnosed with pulmonary tuberculosis and HIV infection at 11 months of age. He 
commenced ART at 15 months with a CD4 count of 310 (11.2%). His ART regimen comprised stavudine 
(d4T), lamivudine (3TC) and efavirenz (EFV). Both his parents tested HIV-positive and his father died of 
HIV-related complications 2 years later.   
One month after starting ART, he had his first GTCS during a febrile illness. At 2 years 11 months of age, 
he had multiple afebrile GTCS and was noted to be drowsy. He was ataxic, had slurred speech and 
regression of his motor milestones. His mother reported that the drowsiness was present since he started 
ART, but the ataxia and slurred speech were new. At this stage, his viral load was less than detectable and 
his CD4 count was 1549 (37%). His cerebrospinal fluid (CSF) had no cells, normal chemistry and was 
negative for herpes simplex viruses (HSV 1 and 2), John Cunningham (JC) virus and Cryptococcus 
neoformans. He had a normal brain CT scan. His EEG showed non-specific generalized slowing and no 
evidence of non-convulsive status epilepticus. Antiepileptic medication was not initiated. The ataxia 
resolved over a period of 1 month.  
He was re-admitted to hospital at 3 years 6 months of age (7 months after the previous presentation) with 
acute ataxia and drowsiness. His mother was confused about his medication dosage and had given him 
650 mg daily of efavirenz for 2 weeks instead of the prescribed 250 mg. His CSF and a repeat brain CT scan 
were normal. A repeat EGG showed no evidence of non-convulsive status epilepticus. His plasma efavirenz 
level was 69.0 mg/L (normal range 1-4 mg/L). Efavirenz was discontinued, leaving his ART regimen as 
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d4T/3TC. Over 2 weeks, repeated checks of his plasma efavirenz level showed a decrease from 69.0 mg/L 
to 54.4 mg/L, 36.9 mg/L and 15.2 mg/L. The ataxia resolved after 2 weeks of stopping the efavirenz.  
Efavirenz was restarted after 3 weeks and repeated plasma efavirenz levels performed at 1 and 3 weeks 
remained elevated (12.9 mg/L and 12.0 mg/L respectively). The treatment with efavirenz was continued. 
Two months later, at age 3 years 9 months old, he was readmitted to the emergency unit with prolonged 
generalized seizures which required phenobarbital loading. After recovery, he was ataxic. EEG showed 
generalized slowing and no evidence of subclinical status epilepticus. Efavirenz levels were not performed 
during this admission. He commenced sodium valproate for seizure management.   
At age 3 years 11 months, he was admitted again with GTCS and ataxia. Plasma efavirenz level was 36.4 
mg/L. At this stage, he was diagnosed as efavirenz neurotoxicity and treatment with efavirenz stopped. 
Repeated plasma efavirenz level 5 days after stopping was 28.0 mg/L. He started lopinavir/ritonavir 
(LPV/r) together with d4T and 3TC. Two months after stopping efavirenz, there were no further seizures, 
drowsiness or ataxia. Plasma efavirenz level rechecked was 0.4 mg/L. He was thought to be a slow 
metabolizer.  
Over the next 2 years, he remained virologically suppressed on d4T/3TC/LPV/r. His mother who herself 
continued on efavirenz was twice documented to be “slow” at clinic. Her mid-dose plasma efavirenz level 
performed during a clinic visit was 4.3 mg/L, just above the upper limit of normal.  
This boy had no further complaints of seizures, drowsiness or ataxia. His antiepileptic treatment was 
stopped at age 7 years after a 2-year seizure-free period. At 8 years of age, he repeated grade 1 with a 
report from his school teacher indicating poor numeracy skills. Neuropsychology assessment documented 
a full-scale IQ score of 48 (extremely low range) with extremely low verbal comprehension, perceptual 
reasoning, working memory and processing speed, with poor executive functioning.  
Patient 6 is a black female aged 8 years 4 months when referred in 2012. She was in foster care as both 
parents were deceased from HIV-related complications. She had prenatal exposure to alcohol and was 
diagnosed with pulmonary tuberculosis and HIV infection at age 3 years 9 months old.  
She commenced first-line ART (d4T/3TC/EFV) at 6 years old. After 21 months of treatment, stavudine was 
changed to abacavir (ABC) due to lipodystrophy of her face. After 28 months on efavirenz, she was 
referred to the Neuro-HIV clinic because of poor memory, drowsiness during school hours and nocturnal 
enuresis. Despite sleeping adequately at night, it was difficult to arouse her in the morning and she often 
fell asleep in school. Drowsiness and sleep disturbances manifested within a few weeks after starting first-
line ART. She struggled academically in second grade mainstream education, which her teacher attributed 
to poor concentration and memory. Although she had no formal cognitive assessment prior to efavirenz 
initiation, both foster parent and school teacher noticed changes in her cognition. 
At presentation to the Neuro-HIV service, aged 8 years 4 months, she was stunted, underweight for age 
and had microcephaly. She had no features of foetal alcohol syndrome, was systemically well and had no 
focal neurological deficits. Her “draw-a-person score” was 5 years.  
Her mid-dose plasma efavirenz concentration, performed 2 weeks prior to referral, was above 20.0 mg/L. 
Neurotoxicity was diagnosed and efavirenz was stopped, leaving her on ABC/3TC. A follow-up plasma 
efavirenz level was 0.72 mg/L. Brain MRI showed nonspecific T2-weighted signal abnormalities in the right 
peritrigonal white matter. Neuropsychology assessment showed poor performance in attention, working 
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memory and processing speed. Her overall IQ was 70 (borderline). Five weeks after stopping efavirenz, 
her level of concentration had improved, and she was no longer sleepy during the day. She continued 
treatment with ABC/3TC and recommendation was made for placement in special school. 
 
Discussion 
The children in this study were 8 indigenous African (black) and 4 mixed ancestry with complex socio-
economic circumstances such as being orphans, uninvolved parents or in foster care. Prenatal alcohol 
exposure was reported with foetal alcohol syndrome probable in one child. These factors together with 
the neuroinflammatory effect of HIV itself and the secondary neurological complications result in a 
complex interplay which impacts on the behaviour of the affected children. Frontal lobe dysexecutive 
syndrome in HIV-infected children and adolescents may result from white matter damage leading to 
cognitive and behavioural challenges, including poor concentration and hyperactivity17 and could 
contribute to the neuropsychiatric manifestations seen in this cohort. However, most of the acute 
manifestations in this study were noticed within a few weeks of efavirenz initiation.          
Among the suspected acute neuropsychiatric manifestations of efavirenz, drowsiness and impaired 
concentration were the most common, occurring in 5 out of the 12 children, including the two with high 
plasma EFV concentrations. In 4 of these children, drowsiness occurred a few weeks after starting 
efavirenz-based ART, and in the fifth child at 6 months. The medication was discontinued for the 2 children 
with high plasma efavirenz levels but continued in the other three with resolution of the symptoms over 
time. Drowsiness is be the most common acute CNS manifestation of efavirenz accounting for up to 50% 
of reported cases.5,18 The adverse events seen a few weeks after starting efavirenz typically resolving 
within one to two months,3,4 and may be missed or not reported, especially in children. Night-time dosing 
is recommended to reduce the effect on the patient’s concentration.3  
Seizures were the second common manifestation in our cohort. They were reported in 4 out of the 12 
children, all treated with valproate with good outcomes, although 1 child required efavirenz 
discontinuation in addition to AED treatment. The incidence of seizures is generally higher in HIV-infected 
children.19 Our study numbers were too small to establish a causal relationship between efavirenz 
initiation and seizures. However, there are 3 reported cases of seizures in black South African children 
following efavirenz initiation that required cessation of treatment before seizure control was achieved.13,15 
All 3 children expressed the CYP2B6 polymorphism rendering them slow metabolizers. Status epilepticus 
is reported in an adult following marked efavirenz toxicity and required treatment discontinuation.20 In 
other reports, children continued treatment with efavirenz as seizures were controlled.21  
Sleep disturbances are commonly reported22 and were documented in 2 of our children. These included 
insomnia and difficulty waking from sleep in the morning despite adequate night-time sleep. In one 
patient, this resolved despite continued treatment with efavirenz, but in the other patient it persisted 
until efavirenz was discontinued. The assumption that sleep disturbances are transient and resolve with 
time despite continued treatment with efavirenz 3,4,21 may not be true for slow metabolizers who maintain 
high and toxic plasma levels even after ingestion of therapeutic doses. There were no nightmares or vivid 
dreams reported by our children, but caregivers may not have been asked about their presence. These 
are commonly reported by adults or adolescents.22,23  
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Ataxia was noticed in one patient with high plasma concentrations of efavirenz. On stopping the 
medication, there was a gradual improvement in the gait with a corresponding decline in the plasma 
levels. Ataxia is reported in other black South African children with supra-therapeutic efavirenz levels.14 
Other acute CNS manifestations seen in our children included behavioural or personality changes such as 
emotional outburst and withdrawn behaviour. Other psychiatric reactions such as hallucinations, 
depression and suicidal ideation were not reported by our children, but are recognized more in adults and 
adolescents.24,25 
Long-term manifestations included poor working memory, attention span, verbal comprehension, 
perceptual reasoning, processing speed and visuospatial skills, as well as poor executive functioning and 
borderline to extremely low IQ (ranging from 48 to 70), all of which can lead to poor academic 
performance. Poor neurocognitive outcomes following long-term efavirenz use, particularly decreased 
verbal fluency, working memory and processing speed, are reported in adults.6 In children, such outcomes 
are often attributed to HIV-associated neurocognitive dysfunction (HAND) or HIV encephalopathy 
(HIVE).26,27 In our cohort, developmental assessments also revealed delayed fine motor, speech and 
language development in 3 children. While these developmental challenges cannot solely be attributed 
to efavirenz as children with HIVE typically have developmental delays,16,27 efavirenz may be exacerbating 
these outcomes. Nine of the 12 children were diagnosed as HIVE/HAND and 1 as attachment disorder. All 
10 children continued their treatment with efavirenz-containing ART.      
Mid-dose plasma efavirenz concentration in 8 children were within the normal reference range of 1-4 
mg/L. Two patients both of indigenous African (black) ancestry, had high (toxic) levels. Their acute 
presentations included drowsiness, ataxia, slurred speech, seizures and sleep disturbance. In the long-
term, they had low achievements in verbal comprehension, perceptual reasoning, attention, working 
memory, processing speed, executive functioning and full IQ score. School reports showed poor numeracy 
skills leading to academic underachievement.  In both children, plasma EFV levels decreased weeks after 
stopping treatment with efavirenz. Their phenotype was compatible with the CYP2B6 SNP making them 
slow metabolizers of efavirenz and predisposing them to neurotoxicity.    
 
Limitations of the study 
The content of this case series is limited by the retrospective data collection. There were no cognitive or 
developmental assessments documented at the time of efavirenz initiation. Further, only 6 and 4 children 
respectively had these assessments as part of their evaluation after referral to neurology. Not all children 
had plasma EFV levels performed, and there was no controlled timing for the EFV levels. It therefore does 
not establish a causal relationship between efavirenz neurotoxicity and neuropsychiatric manifestations. 
Limited access to genetic testing did not allow CYP2B6 genotyping in this study.    
              
Conclusion 
In this retrospective study, 12 children with complex socio-economic status and on efavirenz-based ART 
were referred to neurology service for suspected efavirenz neurotoxicity. The acute presentations 
included drowsiness, seizures, sleep disturbances, ataxia, slurred speech and behavioural or personality 
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changes. The observed long-term outcomes included poor processing speed, attention span, working 
memory, verbal comprehension, perceptual reasoning, visuospatial ability, executive functioning and low 
IQ leading to poor academic performance. Delayed fine motor skills as well as speech/language delay were 
also noted.  
Two children with toxic levels of efavirenz had neuropsychiatric manifestations related to efavirenz. An 
adverse efavirenz response was suspected for the remaining children. The complex interplay of the 
difficult socio-economic circumstances in these children, the neuroinflammatory effect of HIV and the 
secondary complications from opportunistic infections and other treatment besides efavirenz reflect the 
layering effect of HIV. To better understand the acute neuropsychiatric and long-term neurocognitive 
complications of efavirenz in South African children, a prospective study is needed to compare the 
manifestations of HIV-infected children treated with efavirenz and efavirenz-naïve controls. 
Pharmacogenetic analysis will be important to further understand the risk factors for efavirenz 
neurotoxicity in children including the role of the CYP2B6 polymorphism. 
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Table 1: Study summary 
Total no. of children referred (N) 12 children 
Period of study January 2008 – December 2014 
Age distribution Range 3 years 4 months to 12 years, mean 7 years 8 months, median 8 years 5 months 
Sex distribution 5 males, 7 females 
Racial distribution 8 blacks, 4 mixed, 0 whites, 0 Asians 
Neuroimaging studies (n=8/12) 3 had brain CT scans: all normal (3/3) 
5 had brain MRI; normal (3/5), non-specific signal changes (1/5), old infarcts (1/5) 
Acute neuropsychiatric manifestations (n=6/12) Reported within 2-8 weeks after EFV initiation (mean 5 weeks) and included drowsiness or impaired 
concentration (5/12), seizures (4/12), sleep disturbances (2/12), behavior and personality changes (2/12), 
acute ataxia (1/12), and slurred speech (1/12) 
Neurocognitive or developmental assessment (n=11/12) 11 had some form of assessment including neuropsychology testing (n=6), developmental assessment (n=4) 
and school report (n=7). Neurocognitive and developmental difficulties were noted after 6-72 months on EFV 
(mean 31 months)   
Neuropsychology reports (n=6/12) All 6 children showed borderline, low or extremely low achievements in all domains including poor processing 
speed (5/6), attention span (4/6), working memory (3/6), verbal comprehension (2/6), perceptual reasoning 
(2/6), executive functioning (1/6), visuospatial ability (1/6) and borderline to extremely low IQ (5/6). 
Developmental assessment reports (n=4/12)  Delayed fine motor development (3/4) 
Delayed speech/language development (2/4) 
Age-appropriate development (1/4) 
School (or teacher’s) reports (n=7/12) 6 children not coping with mainstream curriculum, with 5 repeating various grades 
1 child had average performance in mainstream curriculum 
Duration on efavirenz before presentation Mean duration at the time of acute presentation = 5 weeks (range 2-8 weeks, median 4 weeks) 
Mean total duration at the time of neurocognitive or developmental assessment = 31 months (range 6-72 
months, median 23 months) 
Total duration not known for 2 patients  
Plasma EFV levels (n=10/12)  Levels within normal range of 1-4 mg/L (8/10)  
Levels above normal range (2/10) 
Neurologic diagnoses and outcomes EFV neurotoxicity, EFV stopped (2/12) 
HAND/HIVE, EFV continued (9/12) 
Behavioural disorder, EFV continued (1/12) 












Socioeconomic status and relevant 
history 
Reason(s) for referral to 
neurology 
Clinical, Laboratory &  
Neuro-radiological findings 
School report, Developmental assessment 
& Neuropsychology assessment (age at 
report) 
1 2008 3y 6mo 
Male 
Black 
Lived with mother (HIV+) and 5-year old 
sister (HIV-). Father died (HIV-related) 
when he was 3y old. Diagnosed HIV+ at 
age 11mo when he presented with FTT, 
PTB and pericardia effusion. Started 
ART at age 15mo. 
   
Drowsiness and seizures 
(GTCS) few weeks after 
starting EFV. Had acute 
ataxia (with regression of 
motor milestones) and 
slurred speech after he 
was accidentally 
dispensed with high doses 
of EFV.   
Clinical: Underweight for age and 
sex. WHO stage 3 disease.  
Lab: Low CD4 count = 310 (11%) at 
commencement of ART. 
EEG: non-specific generalized 
slowing (x2), normal (x1). 
Audiology: normal hearing 
Neuroimaging: normal brain CT 
scan 
School report (grade 2, age 8y 6mo): 
Functioning below average in all areas. 
Poor numeracy skills.  
Neuropsychology report (age 9y 0mo): 
borderline to extremely low verbal 
comprehension, low average to extremely 
low perceptual reasoning, extremely low 
working memory and borderline to 
extremely low processing speed. Low 
achievement on executive functioning. Full 
IQ score 48 (extremely low). 
2 2008 3y 4mo 
Male 
Black 
Lived with mother who was diagnosed 
HIV+ during pregnancy. No antenatal 
PMTCT but had AZT after birth for 6 
weeks. No NVP. Diagnosed HIV+ at age 
4mo. Father was not involved with 
care. Started ART at age 21mo. History 
of poor adherence to ART 
Reported insomnia 2mo 
after starting EFV. 
Seizures (GTCS) and 
impaired concentration 
reported 6mo after EFV.  
Clinical: Well grown, hyperactive 
child with poor concentration. 
WHO stage 2 disease  
EEG: Normal awake and sleep EEG. 
Neuroimaging: normal brain CT 
scan 
Not available 
3 2009 4y 4mo 
Male 
Black 
Diagnosed HIV+ at age 3mo. Mother 
was sole caregiver until she died of HIV-
related condition. Father was not 
involved. Child placed in institutional 
care at age 3y. Started ART at age 
78mo. Father came back into the 
picture when he was 7.6y old. He then 
moved in with father and step mother. 
History of PTB, FTT, delayed speech and 
ADHD. Started treatment with 
methylphenidate at age 6y 3mo. 
Seizures (staring, GTCS) 
and impaired 
concentration.  GTCS 
started before ART 
initiation but staring and 
impaired concentration 
started 6 weeks after EFV. 
Clinical: Normal weight and height 
for age and sex, but microcephalic. 
Hyperactive with mild to moderate 
speech delay.  
EEG: Normal awake and sleep EEG. 
Audiology: normal hearing 
Neuroimaging: Brain CT scan 
showed calcified mastoid air cells, 
normal brain parenchymal 
Developmental assessment (age 7y 2mo): 
Delayed fine motor and speech/language 
development. At chronological age of 
86mo, his fine motor development was 
assessed at 64mo and his language 
development at 66mo.   
Conner’s questionnaire: completed by 
both teacher and carer (at age 6y 3mo) 
suggestive of ADHD. 
4 2010 10y 
Female 
Black 
Forster care (lived with uncle). Mother 
deceased, no information on father. 
Pregnancy/birth history not known and 
no details on when and how HIV was 
diagnosed and duration on ART.   
Poor concentration 
affecting school work  
Clinical: Stunted with long tract 
signs in the lower limbs. 
Audiology: Normal audiogram 
(had poor concentration during 
testing 
Neuroimaging: Not done 
School report (grade 2, age 10y): Struggling 




5 2012 6y 10mo 
Male 
Mixed 
Forster care. Both parents deceased 
(HIV-related). History of alcohol 
exposure in utero, and FTT, PTB and 
parotitis at age 13mo. Started ART at 
25mo. Diagnosed ADHD at age 6y and 
was being treated with 
methylphenidate.    
Poor concentration and 
ADHD. 
Clinical: Stunted and 
microcephalic. Had FAS facies, 
features of ADHD and long tract 
signs.  
Audiology: Normal hearing but 
slow in responses (needed lots of 
reinforcement during testing). 
Neuroimaging: normal brain MRI 
Neuropsychology report (age 7y 2mo): 
Borderline verbal comprehension, 
borderline perceptual reasoning, low 
working memory, extremely low processing 
speed. Verbal IQ 70 (borderline), 
Performance IQ 70 (borderline), Full scale 
IQ 62(extremely low) 
Conner’s questionnaire:  completed by 
foster parent and teacher (at age 6y) 
suggest ADHD 
6 2012 8y 4mo 
Female 
Black 
Forster care. Both parents deceased. 
Mother died of pregnancy-related 
complication when she was pregnant 
with younger sibling. Father died of 
HIV-related cause. History of prenatal 
alcohol exposure and PTB at age 3y + 
10mo. Diagnosed HIV+ at age 3y + 
10mo and started ART at 6y.  
Drowsiness (during school 
hours), difficult to arouse 
during sleep, all noticed 
few weeks after starting 
EFV. Also has poor 
concentration and poor 
memory affecting school 
work.    
Clinical: Stunted and underweight. 
OFC between 3rd-10th centile. No 
features of FAS. No focal signs. 
Noted to be drowsy during clinic 
visit.  
Audiology: Normal testing. 
Neuroimaging: Brain MRI showed 
non-specific T2W high signal 
abnormality in the right 
peritrigonal white matter. 
School report (grade 2, age 8y): Not coping 
with mainstream curriculum. Repeated 
grade 2. 
Neuropsychology report (age 8y 9mo): 
Low performance on attention, working 
memory and processing speed. (Was 
drowsy during testing). Full scale IQ 70 
(borderline) 
7 2013 10y 1mo 
Female 
Black 
Lived with both parents, (both HIV+) 
and 2 older siblings (both HIV-). Mother 
tested HIV- during pregnancy. Had 
normal early development and 
generally good health until age 8y when 
she was diagnosed HIV+. Started ART at 
8y. 
Poor concentration and 
poor memory affecting 
school work leading to 
school failure. 
 
Clinical: Well grown. Had low 
central tone, brisk reflexes with 
spread and crossed adductors. 
Mirror movement with finger 
apposition.  
Audiology: Normal testing. 
Neuroimaging: Brain MRI showed 
old lacuna infarct 
School report (grade 2, age 10y): slow 
learner. Difficulties with English language 
and Mathematics. Repeated grade 2 in 
mainstream curriculum. 
Developmental assessment (age 10y 1mo): 
Poor fine motor skills. Draw-a-person score 
of 5y (at chronologic age of 10y 1mo old).  
Neuropsychology report (age 10y 7mo): 
Extremely low attention, processing speed, 
verbal comprehension and perceptual 
reasoning. Intact memory. Verbal IQ 55 
(extremely low), performance IQ 69 
(extremely low) full scale IQ 60 (extremely 
low) 
8 2013 12y 
Female 
Mixed 
Lived with both parents (both HIV+). 
Had a younger sibling who is HIV-. 
Diagnosed HIV+ at age 4y. History of 
PTB at 5y. Started ART at 5y.  
Poor concentration and 
poor school performance.  
Clinical: Well grown. All growth 
parameters above 50th centile. Had 
long tract signs in all limbs. 
Audiology: Normal testing. 
Neuroimaging: Normal MRI 
School report (grade 3, age 12y): Struggling 
with mainstream curriculum (repeated 
grades 1 and 3) 
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9 2013 5y 5mo 
Female 
Black 
Failed PMTCT. Separated from 
biological mother on day 2 of life and 
placed in “place of safety” until 
adopted at age 4mo. Normal early 
development. Diagnosed HIV+ before 
age 1y and started on ART at age 24mo.  
Withdrawn behavior, 
emotional outburst 
(usually at home, never at 
school, and terrible on 
holidays)  
Clinical: Well grown, normal 
neurologic and systemic 
examination.  
EEG: Normal background, sharply 
contoured activity noted 
bilaterally.  
Neuroimaging: not done 
Developmental assessment (age 5y 5mo): 
Development assessed to be age 
appropriate. Draw-a-person score of 5y 
7mo (at chronologic age of 5y 5mo old) 
10 2014 8y 6mo 
Female 
Mixed 
Lived with mother (HIV+), father was 
not involved. Diagnosed HIV+ at age 6y. 
Previous history of LRTI in infancy 
requiring hospital admission. Had 
normal early development. Has 2 older 
siblings from a different father, both 
HIV-. Started ART at age 8y.  
Poor concentration, 
emotional outburst and 
personality changes 
noticed about 2 months 
after starting EFV 
Clinical: Microcephalic. Weight 
and height above the mean for age 
and sex. Had brisk DTR with 
clonus.  
Audiology: normal hearing 
Neuroimaging: Brain MRI normal 
Neuropsychology report (age 8y 11mo): 
Low average general intellectual 
functioning and processing speed, severe 
to profound impairment in attention and 
visuospatial ability, borderline working 
memory, visual memory and executive 
functioning 
11 2014 9y 4mo 
Male 
Black 
Lived with mother (HIV+). Father 
deceased (HIV status unknown). History 
of PTB and FTT at age 11mo when HIV 
was diagnosed. Started ART at 13mo. 
Developed hypersensitivity (rash) to 
ABC and lipoatrophy on AZT. At time of 
referral, was on 3TC/EFV.  
Poor concentration 
leading to school failure.  
Clinical: All growth parameters 
>50th centile for age and sex. 
Normal neurologic examination. 
Audiology: normal hearing. 
Neuroimaging: Not done. 
Developmental assessment (age 3y 9mo): 
At chronologic age of 45mo, had significant 
delay in speech (+/- 30mo) and fine motor 
development (30-36mo).  
School report (grade 3, age 9y): repeated 
grade 1, passed grade 2 and was struggling 
with mainstream curriculum in grade 3.  
Neuropsychology report (age 9y 9mo): 
Marked difficulty with attention, processing 
speed and language. Memory (verbal and 
visuospatial) spared. 
12 2014 10y 6mo 
Female 
Mixed 
Lived with grandparents. Mother (HIV+) 
was on illicit drugs (died when patient 
was 6y old). Father not involved. 
Previous PTB and FTT. Diagnosed HIV+ 
at age 14mo and started on ART at age 
17mo. History of poor adherence to 
ART. Referred by school teacher who 
reported episodes of absent stares 
lasting briefly after which she becomes 
sleepy. 
Seizures (staring) and 
drowsiness few weeks 
after EFV initiation.   
Clinical: Microcephalic with long 
tract signs. WHO stage 4 disease. 
Lab: FBC showed pancytopaenic 
picture.  
EEG: Awake EEG normal 
Neuroimaging: Not done 
School report (grade 4, age 10y): Pursuing 
mainstream curriculum with average 
performance. 
Key:  3TC, lamivudine; ABC, abacavir; ADHD, attention deficit hyperactivity disorder; ART, antiretroviral therapy; AZT, zidovudine; CT, computerized 
tomography; DTR, deep tendon reflexes; EEG, electroencephalogram; EFV, efavirenz; FBC, full blood count; FTT, failure to thrive; GTSC, generalize tonic-clonic 
seizures; HIV+, HIV-positive; HIV-, HIV-negative; mo, month(s); IQ, intelligence quotient; MRI, magnetic resonance imaging; NVP, nevirapine; OFC, occipito-
frontal circumference; PMTCT. Prevention of mother to child transmission; PTB, pulmonary tuberculosis; WHO, World Health Organization; y, year(s). 
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Table 3: Details of EFV treatment and reported neuropsychiatric and neurocognitive manifestations 
No Total duration on 
EFV (months) 
Acute neuropsychiatric manifestations 






1 20 Drowsiness [0.5 month] 
Seizures (GTCS) [1 month] 
Acute ataxia and slurred speech [after 
accidental ingestion of high doses EFV for 2 
weeks] 
 
Low verbal comprehension 
Poor perceptual reasoning 
Poor working memory 
Poor processing speed 
Low executive functioning  
Extremely low IQ 
Poor academic performance 




Diagnosed as EFV neuro-toxicity. EFV 
discontinued. Levels rechecked 2 months 
after discontinuation was 0.4 mg/L. 
Seizures treated with valproate which 
was weaned after 2-year seizure-free 
period. Discharged from neurology at 
age 8y 6mo (5 years after seizure onset) 
2 22 Insomnia [2 months] 
Seizures [6 months] 
Impaired concentration [6 months] 
 
None reported Not done Diagnosed as HAND. Seizures treated 
with valproate with good seizure control 
once adherent. Continued treatment 
with EFV 
3 9 Seizures (staring episodes) [1.5 months] 
Impaired concentration [1.5 months] 
 
Delayed fine motor skills 
Delayed speech/language 
development 
2.70 Diagnosed as HIVE. Treated with 
valproate and methylphenidate. Had 
speech therapy. Continued treatment 
with EFV + d4T/3TC with virologic 
suppression, and no worsening of 
seizures. Relocated to another province 
at age 8 years.  
4 Not known None reported Poor academic performance 1.04 Diagnosed as HIVE/HAND. Continued 
treatment with EFV 
5 Not known None reported Poor working memory 
Poor processing speed 
Extremely low IQ 
2.04 Diagnosed as HIVE, FAS, ADHD. 
Continued treatment with EFV.  





Drowsiness [0.5 month] 
Sleep disturbances [0.5 month] 
Poor working memory  
Poor attention 
Poor processing speed 
Borderline IQ  





Diagnosed as EFV neurotoxicity 
Discontinued treatment with EFV. Levels 
rechecked 2 weeks later was 0.74 mg/L. 
Special schooling was recommended 
7 24 None reported Delayed fine motor skills 
Low verbal comprehension 
Poor attention 
Poor perceptual reasoning 
Poor processing speed 
Extremely low IQ 




Poor academic performance 
8 64 None reported 
 
Poor academic performance 3.90 Diagnosed as HAND/HIVE. Continued 
treatment with EFV. Discharged from 
neuro. 
9 12 Withdrawn behavior [duration on EFV not 
clear] 
Emotional outburst behavior [duration on 
EFV not clear] 
None reported 1.28 Diagnosed as behavioural disorder 
(attachment disorder). Referred to 
psychiatry 
10 6 Emotional outburst [2 months] Impaired attention 
Impaired visuospatial ability  
Not done Diagnosed as HIVE. Continued treatment 
with EFV 
11 72 None reported 
 
Speech/language delay 
Delayed fine motor skills 
Poor attention 
Poor processing speed 
Poor academic performance 
0.8 Diagnosed as HAND. Continued 
treatment with EFV. Special schooling 
and speech therapy recommended. 
Further f/up at district hospital 
12 26 Seizures (staring episodes) [0.5 month] 
Drowsiness [0.5 month] 
None reported 1.7 Diagnosed as HIVE. Treated with 
valproate with good seizure control. 
Continued treatment with EFV 
Key:  3TC, lamivudine; ADHD, attention deficit hyperactivity disorder; d4T, stavudine; EFV, efavirenz; FAS, foetal alcohol syndrome; FTT, failure to 








Appendix 1: Data Collection Form 
Study ID: [  ][  ][  ]    Patient’s folder number:[  ][  ][  ][  ][  ][  ][  ][  ][  ][  ] 
Referred from: ………………………………………………………………………………………………………………………………… 
 
a. Demographic details and relevant histories   
DOB: __ __/__ __/__ __ __ __ (dd/mm/yyyy)  Sex:  [  ] Male [  ] Female 
Race: [  ] Indigenous African (Black)  [  ] Asian   
[  ] European ancestry (White)  [  ] Mixed ancestry      
Date diagnosed as HIV positive: __ __/__ __/__ __ __ __ (dd/mm/yyyy) [  ] Not known 
Age at diagnosis: ……..….. months  [  ] Not known 
Social status at the time of referral:  [  ] Orphan  [  ] Semi-orphan  
[  ] Not an orphan [  ] Not known 
Primary caregiver(s):  [  ] Parents  [  ] Other family member/foster care  
[  ] Institutional care [  ] Other (specify): ………………………………………………………..  
School type:  [  ] Mainstream  [  ] Special education (specify): ………………………..………..……………… 
  [  ] Not placed 
School grade: ………………………………. 
Teacher’s report (if available): …………………………………………………………………………………………………………………. 
              …………………………………………………………………………………………………………………. 
Other affected family members:  [  ] Yes   [  ] No  [  ] Not known 
       If Yes, specify: ………………………………………………………………………..…. 
Comorbidities: [  ] PTB    [  ] Meningitis   [  ] Seizures (≥2x)  
[  ] ADHD  [  ] Developmental delay  [  ] Other ………………………………… 
Details of comorbidities: ………………………….………………………………………………………………………………………………. 
 ……………………….………………………………………………………………………………………………….. 
Other relevant histories: …………..……………………………………………………………………………………………………………… 
   …………….……………………………………………………………………………………………………………… 
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b. Physical findings (at the time of referral) 
Anthropometry:   Weight: [  ][  ].[  ][  ] kg  Percentile: ………………………………   
Height: [  ][  ][  ] cm Percentile: ………………………………   
OFC: [  ][  ] cm  Percentile: ……………………………… 
Neurological examination:  ….…………………………………………………………………………………………………………… 
    ………………………………………………………………………………………………………………. 
    ………………………………………………………………………………………………………………. 
Other relevant findings: ……………………………………………………………………………………………………………… 
   ………………………………………………………………………………………………………………. 
   ………………………………………………………………………………………………………………. 
 
c. Laboratory investigations and Neuroimaging (at the time of referral or within 3 months) 
Absolute CD4 count: …………….………. CD4%: ………………..…….… WHO staging: ……………………… 
Viral load: ……………………………………… 
Blood counts: FBC: Hb …………… g/dL MCV…………………. WBC……………….. PLT…………………. 
LFTs:   ALT…………………. AST…………………… GGT………………… T.Bil……………….. 
Electroencephalogram (EEG): [  ] Yes  [  ]No 
If yes, findings: ………………………………………………………………………………………………………………. 
    ………………………………………………………………………………………………………………. 
Neuroimaging:  [  ]Brain CT scan [  ] Brain MRI 
  Findings: …………………………………………………………………………………………………………………………. 
   ……………………………………………………………………………………………………………………………. 
Audiogram:  [  ] Yes  [  ] No 








d. Antiretroviral treatment and plasma EFV levels  
First-line ART regimen: ………………………………………………………….. Date started: _ _/_ _/_ _ _ _ (dd/mm/yyyy) 
Is patient still on first-line ART?   [  ] Yes  [  ] No 
If no, date stopped: _ _/_ _/_ _ _ _ (dd/mm/yyyy) 
Reason for stopping: ………………………………………………………………………………………………………………… 
Second-line ART regimen: ……………………………………………………… Date started: _ _/_ _/_ _ _ _ (dd/mm/yyyy) 
Is patient still on 2nd-line ART?   [  ] Yes  [  ] No 
If no, date stopped: _ _/_ _/_ _ _ _ (dd/mm/yyyy) 
Reason for stopping: ………………………………………………………………………………………………………………… 
Total duration on EFV:  ………………….. months 
Plasma EFV levels: [  ] Yes  [  ] No 
 If yes, give details:  Date: _ _/_ _/_ _ _ _  EFV level: ……………………….. mg/L 
    Date: _ _/_ _/_ _ _ _  EFV level: ……………………….. mg/L  
    Date: _ _/_ _/_ _ _ _  EFV level: ……………………….. mg/L 
Other chronic medications besides ARTs: [  ]Yes  [  ] No 
 If yes, specify:  ……………………..…………..…….……..  
…………………………………………..…… 
 
e. Acute Neuropsychiatric manifestations 
1. Neuropsychiatric manifestation: ………………………………………………………………………………… 
Date first reported/identified: _ _/_ _/_ _ _ _  Date resolved: _ _/_ _/_ _ _ _ 
How was it managed:  [  ]EFV continued    
[  ]EFV dose modified at clinic 
   [  ]EFV stopped temporally by patient/caregiver 
   [  ] EFV stopped temporally at clinic   
[  ]EFV discontinued by parent/caregiver 
[  ]EFV discontinued at clinic 
Other details:  ……………………………………………………………………………………………………………………………. 
  ……………………………………………………………………………………………………………………………. 
  ……………………………………………………………………………………………………………………………. 
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2. Neuropsychiatric manifestation: ………………………………………………………………………………… 
Date first reported/identified: _ _/_ _/_ _ _ _  Date resolved: _ _/_ _/_ _ _ _ 
How was it managed:  [  ]EFV continued    
[  ]EFV dose modified at clinic 
   [  ]EFV stopped temporally by patient/caregiver 
   [  ] EFV stopped temporally at clinic   
[  ]EFV discontinued by parent/caregiver 
[  ]EFV discontinued at clinic 
Other details:  ……………………………………………………………………………………………………………………………. 
  ……………………………………………………………………………………………………………………………. 
  ……………………………………………………………………………………………………………………………. 
 
3. Neuropsychiatric manifestation: ………………………………………………………………………………… 
Date first reported/identified: _ _/_ _/_ _ _ _  Date resolved: _ _/_ _/_ _ _ _ 
How was it managed:  [  ]EFV continued    
[  ]EFV dose modified at clinic 
   [  ]EFV stopped temporally by patient/caregiver 
   [  ] EFV stopped temporally at clinic   
[  ]EFV discontinued by parent/caregiver 
[  ]EFV discontinued at clinic  
Other details:  ……………………………………………………………………………………………………………………………. 
  ……………………………………………………………………………………………………………………………. 












f. Long-term neurocognitive outcome 
1. Neuropsychology assessment:  [  ]Yes  [  ] No 
Date of assessment: _ _/_ _/_ _ _ _  Chronologic age: ………………………. (months) 
Assessment tool/scale: ………………………………………………………………………………………………………………. 
Results of assessment and interpretation  
Verbal comprehension: 
 Similarities: ……………………………………………………….………………………………………………. 
 Vocabulary: ……………………………………………………….……………………………………………... 
 Comprehension: ……………………………………………………………………….………………………. 
Perceptual reasoning:  
 Block design: ……………………………………………………………………………………………………… 
 Picture concepts: ………………………………………………………………………………………………. 
 Matrix reasoning: ………………………………………………………………………………………………. 
Working memory: 
 Digit span: ……………………………………………………………………………………….………………… 
Letter-Number sequencing: ………………………………………………………………………………. 
Processing speed: 
 Coding: ………………………………………………………………………………………………………………. 
 Symbol search: …………………………………………………………………………………………………… 
Executive functioning:  
Visuospatial planning: ………………………………………………………………………………………… 
Problem solving: ………………………………………………………………………………………………… 
Frustration tolerance: …………………………………………………………………………………………  
Ability to understand and follow rules: ………………………………………………………………. 
 Attention span: ……………………………………………………………..…………………………………… 
Intelligence Quotient 
Verbal IQ score: …………………………………………………………………………………………………. 
Performance IQ: …………………………………………………………………………………………………. 






2. Developmental assessment: [  ] Yes  [  ] No 
Date of assessment: _ _/_ _/_ _ _ _  Chronologic age: ……………………….. (months) 
Assessment scale used: ………………………………………………………………………………………………………….. 
Findings:  
Gross motor: ……………………..……………………………………………………………………………………………. 
Fine motor: …………………………………………………………………………………………………………………….. 
Communication: ……………………………………………………………………………………………………………… 
Personal-Social: …………………….…..………………….………………………………………………………………… 
Other findings:  ………………………………………………………………………………………………………………. 
  ………………………………………………………………………………………………………………. 
 
 
3. School reports:   [  ] Yes  [  ] No 
Grade: ……………………………… Details: ………………………………………………………..…………………………… 
……………………………………………………………………………………… 
     ……………………………………………………………………………………… 
Grade: ……………………………… Details: ……………………………………………………………………………………… 
     ……………………………………………………………………………………… 
     ……………………………………………………………………………………… 
 
 










































Appendix 5: Reviewers’ comments for published paper (chapter 1) 
Title: Neuropsychiatric complications of efavirenz in children with HIV infection 
Reviewer: 1 
1. Several sections of this MS should be broadened/expanded as both the cell count and the 
number of references are quite below the suggested maximum limit. There is a lot of 
information that is simply mentioned without being analyzed in detail. 
2. The authors discuss together “visual disturbances” and “dizziness” but these two effects are 
different and need to be clarified in greater detail. Please address this in the manuscript. 
3. The section “Future perspective” does not correspond with the title of this work as it is only 
general information and no reference to children is made. 
4. The MS would benefit for a global check of the language style. At some points there is 
repetition of information. At other points, the information presented does not flow smoothly. 
These corrections will add value to the MS and make it easier to read. 
5. It would be very helpful to state in the text the plasma concentration of EFV in the clinical 
studies referenced. Is there a link between the EFV plasma concentration and the adverse 
effects observed?? Is there evidence for this in children? 
6. In the main text, the authors should state exactly the age of the children in the studies in 
question if that information is available. The age difference in children may be a crucial 
factor for the side effects detected. The authors should discuss this. 
7. Is there any evidence associating EFV-linked CNS effects and drugs of abuse in pediatric 
population? 
8. Is there evidence that EFV-induced AEs are related to the other ARV drugs in the multidrug 
regime? 
9. The authors state that “Efavirenz is mainly metabolized in the liver by the cytochrome P450 
isoenzyme CYP2B6…”. What is known about this metabolic system in children (in the case 
of other drugs)? Are there changes in the EFV metabolism between adults and children? 
10. What other factors regarding the pediatric subjects studied and referred to in this MS may be 
interfering with the effects recorded for EFV use. Body weight? Sex? Other comorbidities? 
Concomitant confections? 
11. Several statements in the paragraph. “It is well absorbed after oral administration. Following 
a single dose of 600 mg in adults, it reaches a maximum plasma concentration (Cmax) of 4.1 
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mcg/mL in 3-5 hours. After multiple dosing, steady-state concentrations are achieved 
between 6-10 days. It is 99% bound to plasma albumin with an apparent distribution 
volume…” lack references. Please add in relevant references to support the data. 
12. The mechanistic studies regarding the mechanism by which EFV interferes with brain 
function includes assays performed in vitro (ref 8,9, 48). This needs to be clearly stated in the 
MS. Also, there are several other studies performed in vitro or in vivo that have to be 
mentioned (reviewed in Apostolova N et al., JAC, 2015; doi: 10.1093/jac/dkv183). 
13. The paragraph starting “These drug interactions are even more important…”  and the one 
starting with “The panel found that the efavirenz…” should not be separate ones but a 
continuation of the previous paragraph in each case. 




This Review summarizes papers concerning neuropsychiatric complications in children receiving 
efavirenz within HAART regimes. Efavirenz is recommended by the WHO as a first line drug 
and became therefore the most common anti-HIV drug in sub-Saharan countries. It is known that 
one of the most predominant adverse events of efavirenz are neuropsychiatric complications in 
diverse forms. The magnitude often correlates with plasma peak concentrations. These known 
adverse events are quite complicated in children due to body weight and body surface related 
drug dosing and different active CYP2B6 metabolizing enzyme system. All these points are well 
reflected by the authors of this review who did a very good job. 
 
1. In the introduction (Page 3, line31), the authors should consider that efavirenz is supposed to 
induce its own metabolism via CYP2B6 induction, which may shorten its half-life over time. 
Additionally, efavirenz combination with tuberculosis drugs (rifampicin) in HIV/TB co-
infected patients may result in reduced efavirenz plasma levels due to the CYP induction by 
rifampicin. The authors should mention this in the introduction. 
2. In the chapter 'drug interactions', the authors should consider extending it with a focus on the 




Appendix 6: Author Guidelines for Developmental Medicine & Child Neurology  
Updated January 2018 
All papers should be submitted online at http://mc.manuscriptcentral.com/dmcn. Please email the 
editorial office with any queries about the process (dmcn@editorialoffice.co.uk). 
Papers published in Developmental Medicine & Child Neurology (DMCN) are freely available online from 
12 months after publication. Authors who wish to make their papers freely accessible immediately upon 
publication may use Wiley’s pay-to-publish service, OnlineOpen. (See 2 Copyright below.) 
Note to NIH Grantees 
Pursuant to NIH mandate, Wiley will post the accepted version of contributions authored by NIH grant-
holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 
months after publication. For further information, see www.wiley.com/go/nihmandate 
Open access policy in the post-2014 Research Excellence Framework (REF) 
In order to be eligible for submission to the next REF, DMCN is compliant with the REF Open Access 
policy which states authors' outputs must be deposited in an institutional or subject repository after an 
embargo period of 12 months. For further information about the policy, see 
http://www.hefce.ac.uk/media/HEFCE,2014/Content/Pubs/2014/201407/HEFCE2014_04_07updated%2
0July%202015.pdf.  
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4. Selection and publication 
a) Editorial review 
b) After acceptance 
c) After publication 
5. Style points 
 
1. Good publication practice 
The journal follows the guidelines of the International Committee of Medical Journal Editors 
(www.icmje.org) and Wiley's Best Practice Guidelines on Publication Ethics 
(www.wiley.com/bw/publicationethics/). In particular, please note the following points. 
a)    Authorship 
Our criteria for authorship are based on the International Committee of Medical Journal Editors 
guidelines.  More information can be found here: www.icmje.org 
Credit for authorship should be based on:  
1.      substantial contributions to research design, or the acquisition, analysis or interpretation of data;  
2.      drafting the paper or revising it critically;  
3.      approval of the submitted and final versions. 
The corresponding author must state that all the authors have read the manuscript and agreed to its 
being submitted for publication. The covering letter should state that all individuals listed as authors 
meet the appropriate authorship criteria, that nobody who qualifies for authorship has been omitted 
from the list, that contributors and their funding sources have been properly acknowledged, and that 
authors and contributors have approved the acknowledgement of their contributions. The covering 
letter should include a short description of each author’s contribution and should state whether he or 
she had complete access to the study data that support the publication.  
Up to ten authors may be included on the title page. When there are more than ten authors, nine may 
be included on the title page and the tenth slot given to an appropriately named group; the members of 
this group will be listed in an appendix published online only. The authors listed in the study group will 
still be recognised as collaborators of the paper in search engines such as PubMed.  
Contributors who do not qualify as authors should be listed, and their contribution described, in an 
acknowledgement section at the end of the article.  
b)   Reporting guidelines: 
For all Original Articles, Systematic Reviews and Meta-analyses, the Editors and Editorial Board require 
that authors follow the guidelines of the Equator network when reporting research methods and 
findings (http://www.equator-network.org/library/) and the AACPDM Guidelines where appropriate for 




Submissions must be accompanied by the appropriate checklist, fully completed with page numbers 
where applicable. Please select the most suitable checklist from the following and download the 
appropriate checklist: 
• Observational studies (i.e. most Original articles): STROBE guidelines (Click here) 
• Systematic Reviews or Meta-analyses: PRISMA (Click here) 
• Systematic Reviews or Meta-analyses following AACPDM Guidelines: 
Please complete both the PRISMA checklist and the AACPDM checklist (Click here) 
• Randomised controlled trials: CONSORT guidelines (Click here) 
• Other types of study e.g. Diagnostic Accuracy: please visit the Equator website 
http://www.equator-network.org/library/ 
For Editorials, Commentaries, Book Reviews, other types of Review (i.e. not Systematic), Case Reports, 
Letters, and Clinical Insights, no checklist is required. 
c)    Clinical trial registration 
If publishing the results of a clinical trial, please include the clinical trial registration number. All trials 
should be registered in a publicly accessible database. Please upload a copy of the trial protocol as a 
supplementary file.  
d)   Duplicate or related submission 
Authors should declare that the submitted work and its essential substance have not previously been 
published and are not being considered for publication elsewhere. Manuscripts must not be submitted 
simultaneously to another journal. All suspected cases of multiple submissions or redundant publication 
will be subject to investigation. 
If other aspects of the same study were reported previously, are in press, or currently submitted 
elsewhere, this must be clearly indicated in the Methods section, with full referencing. 
e)    Approval and consent 
Ethical approval 
Authors of research articles should demonstrate that the research has been approved by a named 
research ethics committee, that the committee’s recommendations have been adhered to, and that 
written informed consent for participation and publication has been obtained. 
Please include a statement in the text of your paper to indicate that ethical approval has been given and 
give the name of the body (research ethics committee, institutional review board etc.) that approved 
the study. 
If the institution’s research ethics committee did not consider that their approval was needed, this 
should be stated in the text. 
Consent 
Please indicate in the text that patients or their carers have given informed consent to the research and 
to publication of the results. 
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If recognizable photographs or verbal descriptions of an individual are used in an article, written consent 
from the appropriate person(s) for publication must be submitted to, and kept by, the author. All case 
reports and clinical photographs require consent. Names, initials, or any other means of identification 
should not be shown on any photograph. Please use the Consent Form available from the DMCN 
submission site (Click here).  
f)      Disclosures and funding 
Disclosures of interest must be made during the online submission process for authors and during the 
review process for referees. During the online submission process, you will need to clarify the 
involvement of any funder in study design, data collection and analysis, and manuscript preparation. It is 
mandatory that a DMCN Disclosure Form is completed when your paper is submitted, and your paper 
will not be sent for review until we have received your form. ALL authors must sign the DMCN Disclosure 
form before their paper will be published. The form should be submitted to the Editorial Office with 
your manuscript. The DMCN Disclosure form can be found on the submission site 
http://mc.manuscriptcentral.com/dmcn.  
All authors and referees must provide details of financial interests in any company or institution that 
might benefit from the publication of the article. Authors and referees should also declare any other 
potential competing interests that readers or editors might consider relevant to the research submitted 
for publication. In making disclosures, please consider these three areas (please refer to 
http://www.icmje.org/ethical_4conflicts.html for further information): 
1. Financial payments to you or your institution from any sources that might benefit from 
publication of your submission, and any other relevant financial interests (e.g. employment, 
significant share ownership, patent rights, consultancy, research funding);  
2. Similar financial relationships involving your spouse or partner or your dependent children;  
3. Any personal, professional, political, institutional, religious, or other associations that a 
reasonable reader would want to know about in relation to the submitted work. 
All sources of funding or support should be noted in the acknowledgements section of the manuscript 
(including grants from funding bodies, sponsorship or grants from commercial organisations, and 
donation of materials).  
Please note that authors’ disclosures as submitted will be reproduced at the end of your paper when it is 
published.  If no disclosure is made, the following statement will be added to your paper: “The authors 
have stated that they had no interests which might be perceived as posing a conflict or bias.” 
 g)   Misconduct 
If suspicion of misconduct is raised after publication a statement of concern may be issued. All 
complaints or concerns will be investigated. Serious cases of misconduct would result in retraction. 






2.    Copyright  
Authors must declare that the work submitted is their own and that copyright has not been breached in 
seeking its publication.  If the manuscript includes work previously published elsewhere, it is the 
authors’ responsibility to obtain permission to use it and to indicate that such permission has been 
granted. 
Please note that all papers will be assessed using iThenticate® which checks written work for duplicate 
and unattributed content against a large comparison database in order to ensure work is original before 
publication.  
If your paper is accepted, the author identified as the formal corresponding author for the paper will 
receive an email prompting them to login into Author Services; where via the Wiley Author Licensing 
Service (WALS) they will be able to complete the license agreement on behalf of all authors on the 
paper. 
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented with the copyright 
transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed at the 
following link: CTA Terms and Conditions here. Please do not complete this PDF until you are prompted 
to login into Author Services as described above.  
Note to Contributors on Deposit of Accepted Version 
Funder arrangements 
Certain funders, including the NIH, members of the Research Councils UK (RCUK), and Wellcome Trust 
require deposit of the Accepted Version in a repository after an embargo period. Details of funding 
arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Please 
contact the Journal production editor at DMCN@wiley.com if you have additional funding requirements.  
Institutions 
Wiley has arrangements with certain academic institutions to permit the deposit of the Accepted 
Version in the institutional repository after an embargo period. Details of such arrangements are set out 
at the following website: http://www.wiley.com/go/funderstatement.  
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of the following 
Creative Commons License Open Access Agreements (OAA):  
Creative Commons Attribution Non-Commercial License OAA  
Creative Commons Attribution Non-Commercial -NoDerivs License OAA  
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs 
hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.  
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of 
the Research Councils UK (RCUK), you will be given the opportunity to publish your article under a CC-BY 
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license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For 
more information on this policy and the Journal’s compliant self-archiving policy please visit: 
http://www.wiley.com/go/funderstatement.  
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this 
license:  
Creative Commons Attribution License OAA 
To preview the terms and conditions of these open access agreements please visit the Copyright FAQs 
hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html 
 
3.    Presentation and formatting of your paper 
a)    Maximum length requirements 




(excl refs) References 
Figures/ 
tables 
Original article Structured, 
200 words 
1 to 5 points 3000 30 4 
Systematic review Structured, 
200 words 
1 to 5 points As appropriate 
Other review Unstructured, 
150 words 
1 to 2 points 3000 30 4 
Case report Unstructured, 
150 words 
1 to 2 points 1500 15 2 




None None 600 5 0 
Clinical Insights None None 200-300 2 1 
 
b)     All papers 
Title page Include the title of the paper, authors’ full names, main appointments and primary 
affiliations, and word count. Identify the corresponding author and give his or her postal address and e-
mail address. 
We encourage corresponding authors to provide an ORCID (Open Researcher and Contributor ID) 
identifier. ORCID is a registry that provides researchers with a unique digital identifier. Some funding 
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agencies recommend or even require the inclusion of the ORCID in all published articles, and authors 
should consult their funding agency guidelines for details. Registration is easy and free (for funder 
information, see http://orcid.org/). 
Abstract On the second page of original articles and systematic reviews, provide a full structured 
abstract of no more than 200 words, with the following headings: Aim; Method, Results, Interpretation. 
The Aim and Interpretation sections should use plain language, as they will be available openly—that is, 
independent of the main paper. Where relevant the Method section should follow Equator guidelines 
(http://www.equator-network.org/), and should include means (sd) or medians and sex for study and 
control groups, definition of clinical characteristics, entry criteria for study, assessments used, duration 
and frequency of intervention, and timing of outcome assessments. Where relevant “Results” should 
follow Equator guidelines and should summarize significant results with statistical values, including 
negative findings if related to the study hypothesis. Non-significant trends should not be noted in the 
abstract.  
Non-systematic reviews and case reports should have a non-structured abstract without headings of up 
to 150 words, covering the aims, method, results, and conclusions of the study. 
On the abstract page, also provide a shortened form of the title (up to six words) for use as a running 
footer. 
‘What this paper adds’ All original articles and systematic reviews should have a section ‘What this 
paper adds’ after the abstract. This should comprise up to five bullet points up to 12 words. Other 
articles should have one or two similar bullet points. 
The bullet points should contain only new results offered by the paper (i.e. not the paper’s design or 
implications), presented in a direct way. They should be succinct, and preferably they should use plain 
language because the ‘What this paper adds’ section will be openly accessible (that is, free to view by 
anyone). 
General Include tables and figure legends in your main article file, after the references. Submit figures 
(illustrations) as separate files, as described below. Name all files using the surname of the first author 
(e.g. Smith.doc, Smith fig1.tif, etc.). 
c)    Original articles 
Articles should comprise an introductory section (but not headed ‘Introduction’), followed by ‘Method’ 
(with optional subheadings, such as ‘Participants’ [rather than ‘Subjects’] and ‘Statistical analysis’), 
‘Results’, and ‘Discussion’ sections. The Discussion section should include the limitations of the study. 
Subheadings should otherwise be kept to a minimum. 
Authors are encouraged to submit video material supporting their papers, where appropriate, for 
publication in the Journal. 
Papers longer than 3000 words, such as those reporting randomized controlled trials, may be published 
at the Editors’ discretion. 




d)   Reviews 
We publish two types of review. One is a fully detailed comprehensive review of a subject, such as a 
systematic review, with full referencing and a word-count appropriate to the topic and amount of 
material to be covered. The other is intended to be a more personal view providing the reader with up-
to-date information about the subject in question in a relatively brief format, referring to significant 
international papers but not forming a comprehensive overview of the literature. 
 
Authors are advised to refer to the paper by Grant et al: A Typography of Reviews published in Health 
Information and Libraries Journal, 2009, 26:2, before submitting a review paper to DMCN. 
e)    Case reports 
DMCN accepts a very limited number of case reports. These should significantly add to our 
understanding of a condition or present a novel finding. They should comprise an introductory section 
as above, followed by the ‘Case Report’, then a ‘Discussion’ section. 
f)      Letters to the Editor 
Letters are published at the Editors’ discretion. They may comment on a published paper, or raise issues 
that are new to DMCN. In the case of letters commenting on a published paper, normally the author of 
that paper will be invited to comment on the letter, with both letter and comments being published in 
the same issue. The editor may suggest the letter is made available online on the Mac Keith Press 
website, without formal publication, to encourage debate (see 
http://www.mackeith.co.uk/journal/letters-to-the-editor/).  
g)    Clinical Insights 
Clinical images with a description of approximately 200-300 words and one or two references that fit 
within a printed page will be considered for publication in DMCN.  The images can include photographs 
of patients, X-rays, EEGs, and other investigations, videos, or other material considered appropriate by 
the Editors. Images should adhere to the guidelines below (Figures). If a video is submitted please 
submit 2-4 illustrative stills that can be printed in the Journal.  Please also see ‘Approval and Consent’ 
above.   
h)   References 
The Vancouver style is used, as recommended by the International Committee of Medical Journal 
Editors. Cite using a superscript number in the text, with a numerical list of references at the end of the 
paper presented in order of citation. Cite only peer-reviewed, published material. The journal does not 
recognize abstracts or submitted (as opposed to accepted, or ‘forthcoming’) papers as proper citations; 
such material should not be listed with the references but cited only in text, followed by ‘(personal 
communication)’. 
List all authors unless more than six, in which case list the first three followed by ‘et al.’, using Index 
Medicus abbreviations for journal names (see www.nlm.nih.gov/tsd/serials/lji.html). Order and 
punctuate bibliographic information as follows, omitting issue month and number unless needed to 





Abrams RA, Tsai AM, Watson B, Jamali A, Lieber RL. Skeletal muscle recovery after tenotomy and 7-day 
delayed muscle length restoration. Muscle Nerve 2003; 23: 707–14. 
Auvin S, Joriot-Chekaf S, Cuvellier JC, Vallée C. Familial alternating hemiplegia of childhood or 
channelopathy? [letter]. Dev Med Child Neurol 2004; 46: 500. 
Journal Article, online only 
High PC; the Committee on Early Childhood, Adoption, and Dependent Care and Council on School 
Health. School readiness. Pediatrics 2008; 121: e1008–15. 
 
Journal Article, e-pub/online early 
Forsyth R, Basu AP. The change we want to see: the promotion of recovery after acquired brain injury. 
Dev Med Child Neurol 2014 Sep 8. doi: 10.111/dmcn.12575. [E-pub ahead of print].  
Book, whole 
Mesibov GB, Kunce L, Schopler E. Asperger syndrome or high functioning autism? Current issues in 
autism. New York: Plenum Press, 1998.  
Book, chapter 
Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Nelson NM, editors. 
Primary pediatric care. 2nd edition. St. Louis: Mosby Yearbook, Inc., 1992: 1367–78. 
For references to online sources, supply the author names, full title, and full URL including the date on 
which the site was accessed. 
i)      Figures and tables 
Note that the Editors may decide that large figures or tables should be published online-only. 
Tables, figure legends and short appendices Set out on separate pages at the end of (and as part of) the 
main document, after the references. 
Tables and appendices to be published online only Present as separate files in Microsoft Word or Rich 
Text format. 
Figures (e.g. illustrations, charts and photographs) Present electronically as separate files (not in the 
main text of the article). Guidelines about acceptable file formats and illustration preparation are 
provided at authorservices.wiley.com/bauthor/illustration.asp. 
Please label radiographs, CT, or MRI scans with left [L] and right [R], and if appropriate with anterior [A] 
and posterior [P]. Areas of interest should be marked with an arrow. For EEGs please indicate the gain, 
timescale, and lead position. 
Graphs should be as simple as possible, not three-dimensional, and not framed. Shading should be 
white, black, or strong hatching, not grey. No background lines should be used (except for bars and 
axes). 
Colour If colour printing of figures is essential for their comprehension, please indicate this in the 
covering letter. There is normally a charge to the author for printing in colour. It is possible to publish a 
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figure in black and white in the print version of the issue but in colour in the online version at no extra 
charge. Please refer to the Colour Work Agreement (CWA) form for more information. 
Figures should be numbered in order in the text.  A caption must be supplied for each figure.  The 
caption should not repeat what is written in the text material and should follow the Journal style (please 
refer to recent issues for examples).  All captions should be placed in a list at the end of the main 
document. Please remember to supply captions for figures that will be published electronically.  The 
caption must describe all labels in a figure.  For images, the caption should include the type of image, its 
plane, whether or not contrast material was used, the pulse sequence information for MR images and 
the features to be observed by the reader.  However, full details of the MR sequences should be 
described in the methods section, not in the caption. 
j)      Statistical reporting 
The Editors advise reading “Statistical recommendations for papers submitted to Developmental 
Medicine & Child Neurology” (Rigby AS, Dev Med Child Neurol 2010; 52: 299–304) for guidelines on 
appropriate use and reporting of statistical analyses. Authors are recommended to work with a 
statistician where appropriate. 
k)    Supporting information (supplementary material) 
DMCN publishes online supporting information (including audio and video files, data sets, additional 
images, and large appendices) that cannot be included in the print version of an article. This material 
should be relevant to and supportive of the parent article. For guidelines see 
authorservices.wiley.com/bauthor/suppmat.asp. 
 
Authors are encouraged to submit video material to support their papers (e.g. to demonstrate 
techniques or methods, or to demonstrate a randomized controlled trial protocol). 
 
4.    Selection and publication 
a)    Editorial review 
Submissions are subjected to an editorial discussion about their general suitability for the journal. This 
may lead to the decision to not accept the paper, or to send for review by at least two independent 
referees. During the submission process, authors have the opportunity to suggest up to three suitable 
independent referees (with their contact details), but the choice of referee rests with the Editors. At a 
later stage in the review process, papers with statistical analyses undergo specific statistical review. 
Editors and editorial board members are not involved in editorial processes or decisions about their own 
work. 
Reviewers are asked to disclose potential conflicts of interest when they are invited to review a paper 
and when they submit their review. 
Papers thought to have immediate, clinically important consequences may be considered for fast-track 




b)   After acceptance 
After acceptance, authors will be able to track the progress of their article through production to 
publication by registering for Author Services with Wiley. Authors will be sent information about how to 
register for Author Services once their article has been accepted.  
When an accepted paper has been copy-edited and proofed authors will receive a PDF proof. When this 
has been approved by the authors and the paper is ready for publication, it will normally be posted 
online in the journal’s ‘EarlyView’ section before allocation to an issue.  EarlyView articles are in their 
final form and are fully published and citable. 
Authors receive a free PDF of the paper soon after publication via Author Services. Reprints may be 
ordered when returning proofs. Please send no payment: an invoice will be sent shortly after you 
receive the reprints. 
c)    After publication 
Authors are encouraged to promote their articles, for example, through social media. 
If errors affecting the interpretation of data or information are discovered after publication, an erratum 
will be published in the next available issue of the journal and published online. 
 
5.     Style points 
Jargon Avoid it strenuously. The journal aims to communicate across disciplines, and many of its readers 
do not have English as their first language, so plain language is preferred. The Editors may clarify and 
shorten manuscripts accepted for publication as necessary. 
Abbreviations These should be kept to a minimum and restricted to those that are generally recognised. 
They must be spelled out in full on first usage in text and again in figure captions and table footnotes. 
They should be avoided in titles, headings and subheadings. 
Participant details Give mean (SD) age in years and months (not decimal years) and gender (n, not %). 
Ensure this information is included in the abstract. In the text, indicate where study and comparison 
groups are from and how participants were selected. 
Measurements Use SI units, except for blood pressure (mmHg); convert imperial units to metric. Do not 
use percentages for sample sizes below 50; use the symbol ‘%’ in tables. Show standard deviations as 
(SD), not ±. Abbreviate probability with a lower case italicized p, and provided to 3 decimal places when 
possible. 
Numbers In general, use numerals, but spell out numbers at the beginning of sentences. Spell out 
numbers ‘one’ to ‘nine’ if they refer to nouns that are not units of measurement, e.g. ‘The results from 
four children confirm the findings’. For ages and time periods, use years, months, weeks and days, not 
decimals (e.g. 5 years 3 months, not 5.25 years). 
Equipment and drugs Include (in parentheses) the name of the manufacturer, the city, and country of 
production. 
